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Chronic kidney disease in young patients is associated with a high mortality rate due to cardiac events, 
which is in stark contrast to age-matched healthy controls. The mechanisms leading to terminal heart 
failure in chronic kidney disease are, however, still poorly understood.  
Two mouse models of experimental uremia mimicking chronic kidney disease were employed. The 
data acquired were used for extensive correlation analyses, using serum urea levels and microvessel 
density in cremaster muscle (derived from identical animals in a related study) as reference 
parameters.  
Functional parameters were measured in vivo in the cremaster muscle as a model skeletal muscle by 
intravital microscopy techniques. The arterial-venous oxygen saturation difference in uremic animals 
was found to be significantly diminished in a dose-dependent manner. Similarly, in uremic animals, a 
reduced capability to adjust vessel tone was detected. Despite elevated IL-6 serum levels, no reduction 
in leukocyte rolling velocity was shown, which is in line with previous results showing an impaired 
neutrophil recruitment.  
Post mortem analyses of microvessel density in myocardium showed a significant correlation with 
microvascular rarefaction in skeletal muscle detected in vivo, implying that uremia has a systemic 
impact. Aortic cross sections of uremic mice, however, showed normal morphology and no differences 
to controls, suggesting that microvascular rarefaction precedes macrovascular pathology.  
These results indicated chronic hypoxic conditions in the respective tissues. Therefore, the expression 
of genes involved in vessel growth, integrity, and remodeling was determined in cardiac muscle. While 
VEGF-A, Ang-1, and MMP-2 remained unaffected by uremia, HIF 1, VEGFR-2, Tie-1, Tie-2, Ang-2, and 
MMP-9 displayed significant downregulation. Thus, VEGF and Ang/Tie-2 signaling was disrupted in 
uremia, while HIF 1 levels were depleted, suggesting a dysregulated angiogenic response. In fact, 
uremia resulted in a reversed relationship of hypoxia and angiogenesis.  
This study shows that uremia leads, in a dose-dependent manner, to a profound systemic 
dysregulation of the sensitive interplay between physiological and cellular factors needed to maintain 
homeostasis, and this process may already be far advanced before becoming clinically apparent. A 
regulatory network model of feedback loops is presented which may explain the progression of 
disease. Upon continuous damage, the regulatory network may decompensate, resulting in a sudden 
onset of progressively amplifying dysregulatory circles, leading to severe complications which may 
ultimately result in cardiac death. Therefore, microvascular rarefaction is not only an early systemic 
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marker of cardiovascular impairment in chronic kidney disease but also a promising target for future 
therapeutic approaches.   
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Zusammenfassung 
In der pädiatrischen Nephrologie sind chronische Niereninsuffizienz und terminales Nierenversagen 
mit einer sehr hohen Mortalität verbunden. Auffallend dabei ist, dass jungen Patienten im Gegensatz 
zu gleichaltrigen gesunden Kontrollgruppen insbesondere an kardialen Ereignissen versterben. Der 
Pathomechanismus, der bei chronischer Niereninsuffizienz vor allem zum Herztod führt, ist dabei noch 
wenig verstanden.  
In dieser Arbeit wurden zwei Urämie-Mausmodelle zur chronischen Niereninsuffizienz für funktionelle 
Studien eingesetzt. Mit den gewonnenen Daten wurden umfassende Korrelationsanalysen durch-
geführt, wobei Serumharnstoffwerte als Indikator für den Schweregrad der Niereninsuffizienz und die 
Dichte der Mikrovaskulatur des Musculus cremaster (als Modell für einen Skelettmuskel) derselben 
Tiere aus einer parallel durchgeführten Studie als Referenzen genutzt wurden.  
Die arterio-venöse Sauerstoffdifferenz war abhängig vom Urämiegrad der Tiere signifikant reduziert. 
Entsprechend war in urämischen Tieren auch die Fähigkeit zur Regulation des Gefäßtonus 
beeinträchtigt. Trotz erhöhter IL-6-Werte im Serum wurde keine Verminderung der Geschwindigkeit 
des Leukozytenrollens festgestellt. Dies entspricht früheren Studien, in denen bereits eine gestörte 
Rekrutierung von Neutrophilen beobachtet worden war.  
Post mortem-Analysen der Mikrovaskulaturdichte im Myokard zeigten eine signifikante Korrelation zur 
Mikrovaskulatur-Rarefizierung im Skelettmuskel in vivo, was auf einen systemischen Effekt der Urämie 
hindeutete. Aortenquerschnitte urämischer Versuchstiere zeigten jedoch eine normale Morphologie 
ohne Unterschiede zu Kontrolltieren. Dies legte nahe, dass eine Rarefizierung der Mikrovaskulatur der 
Pathologie großer Gefäße vorausgeht.  
Diese Ergebnisse wiesen auf eine chronische Hypoxie in den untersuchten Geweben hin. Daher wurde 
die Expression von solchen Genen im Herzmuskel untersucht, die Gefäßwachstum, -stabilität 
und -remodelling steuern. Während VEGF-A, Ang-1 und MMP-2 durch die Urämie unbeeinflusst 
blieben, waren die Expression von HIF 1α, VEGFR-2, Tie-1, Tie-2, Ang-2 und MMP-9 signifikant 
vermindert. Die VEGF- und Ang/Tie-2-Signalwege waren also bei Urämie gestört, während gleichzeitig 
der HIF 1α-Spiegel vermindert war, was eine Dysregulation der Angiogenese nahelegte. Tatsächlich 
bestand bei Urämie ein reziprokes Verhältnis zwischen Hypoxie und Angiogenese.  
Diese in vivo Studie ergab Hinweise darauf, dass Urämie abhängig von ihrem Schweregrad zu einer 
tiefgreifenden systemischen Dysregulation des empfindlichen Zusammenspiels physiologischer und 
zellulärer Faktoren führt, die zur Aufrechterhaltung einer zellulären Homöostase notwendig sind. 
Dieser Prozess kann bereits weit fortgeschritten sein, bevor er sich klinisch manifestiert. Der 
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Krankheitsfortschritt kann durch ein Netzwerkmodell mit einer Vielzahl von Rückkopplungsschleifen 
erklärt werden. Sobald die Schädigung einen Schwellenwert überschreitet, kann dies zu einer 
Dekompensation durch sich zunehmend selbstverstärkende Rückkopplungsmechanismen führen, die 
schließlich in kardiale Komplikationen münden können. Die Rarefizierung der Mikrovaskulatur bei 
chronischer Niereninsuffizienz ist daher nicht nur ein früher klinischer Marker für drohende kardiale 






1.1 Impaired Renal Function: Major Cause of Premature Death in the Young 
1.1.1 Chronic Kidney Disease and End Stage Renal Disease 
Cardiovascular complications are the leading causes of death in children, adolescents, and adults with 
chronic kidney disease (CKD). The pathomechanisms leading to cardiovascular disease (CVD) while the 
primary defect is located in the kidney, however, are not yet fully understood.  
Normal kidney function is pivotal to maintain body homeostasis and covers, among others, (1) the 
elimination of toxic substances from the blood, (2) the regulation of water and electrolyte balance as 
well as the acid-base equilibrium, (3) blood pressure control, and (4) hormone production. Kidney 
failure has therefore profound effects on health, quality of life, and life expectancy in particular.  
Corresponding to onset and course of the disease, renal failure is classified into acute kidney injury 
(AKI, ICD-10 code: N17), and chronic kidney disease (CKD, ICD-10 code: N18). According to ICD-10, AKI 
is characterized by a sudden loss of renal function with a decrease in glomerular filtration rate, oliguria, 
a rise in serum urea and serum creatinine concentrations. In principle, AKI may be reversible, the 
overall mortality and the risk of developing CKD, however, remains increased (Coca et al., 2012). In 
contrast, CKD develops in most cases as a gradual decrease in renal function and progresses to end 
stage renal disease (ESRD), an irreversible deterioration of renal function. CKD is classified according 
to the glomerular filtration rate (GFR) into 5 stages of renal impairment (table 1). 
Table 1: Staging of Chronic Kidney Disease (adapted from KDIGO 2012 Clinical Practice Guideline 









1  90 Normal kidney function 




Mildly reduced kidney 
function 
Observation, control of blood 
pressure and risk factors 
N18.2 
3 30-59 
Moderately reduced kidney 
function 
Observation, control of blood 
pressure and risk factors 
N18.3 
4 15-29 
Severely reduced kidney 
function 
Planning for end-stage kidney 
failure 
N18.4 
5 < 15 End-stage kidney failure Dialysis or transplant N18.5 
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1.1.2 Etiology and Epidemiology of End-Stage Renal Disease 
Causes for ESRD differ significantly between adults and children. In adults, main risk factors include 
diabetes mellitus type 2, hypertension, and smoking. Other risk factors are application of contrast dyes 
for CT or MRI, the use of analgesics, certain antibiotics, prescription laxatives, or alcohol.  
In contrast, the leading causes of ESRD in children are congenital anomalies of the kidney and urinary 
tract (CAKUT, 33.0 %), glomerular disease (24.6 %), and secondary causes of glomerulonephritis (12.9 
%) (cited percentages refer to the period from 2009 to 2013; US Renal Data System 2015 Annual Data 
Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States; Saran et al., 
2016). In this survey the most common diagnoses associated with ESRD include renal 
hypoplasia/dysplasia, congenital obstructive uropathies, focal glomerular sclerosis, and systemic lupus 
erythematosus.  
1.1.3 Cardiovascular Mortality as a Major Endpoint in Juvenile End-Stage Renal Disease 
The dramatic impact of CKD as an independent risk factor for cardiovascular disease is best illustrated 
by epidemiological studies in young patients. These studies have shown that the cardiovascular 
mortality in young adults with hemodialysis treatment is highly increased and resembles that of 
senescent patients (Foley et al., 1998). Subsequent surveys confirmed that cardiovascular mortality is 
particularly increased in children with ESRD compared to the age-matched general population (Parekh 
et al., 2002, Oh et al., 2002). While cardiac causes account for only 3 % of all deaths in the general 
population of children and young adults (1-24 years, Mathews et al., 2011) they rise to approx. 20 % 
in children and young adults (1-19 years) with a liver transplant and to approx. 30 % in children and 
young adults (1-19 years) undergoing hemodialysis or peritoneal dialysis. The most common cause of 
death in these young patients is cardiac arrest, followed by arrhythmia, cardiomyopathy, and 
cerebrovascular disease (Saran et al., 2016).  
While classical risk factors for CKD in adults were considered rare in children and adolescents, a meta-
analysis revealed that more than 90 % of pediatric patients treated with hemodialysis had at least one 
cardiac risk factor, particularly hypertension and increased serum calcium and phosphate levels 
(Chavers et al., 2011). In addition, uremia-related risk factors such as anemia, volume overload, 
hyperparathyroidism, disturbance of mineral metabolism, or chronic increase of inflammation 
parameters may contribute to the increased cardiovascular mortality, although no study has yet linked 
single risk factors with CVD mortality (Mitsnefes, 2012). However, patients undergoing hemodialysis 
or peritoneal dialysis are more severely affected by cardiovascular morbidity and mortality than 
patients undergoing preemptive transplantation, indicating that uremia plays a key role in the 
development of cardiovascular disease (Foster et al., 2011).  
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Established surrogate markers for cardiovascular disease which can often be found in children with 
ESRD upon thorough investigation are left ventricular hypertrophy (Johnstone et al., 1996), increased 
intima-media thickness (Mitsnefes et al., 2004), increased pulse wave velocity (Covic et al., 2006), and 
tissue calcifications including coronary vessels (Milliner et al., 1990; Oh et al., 2002). For this reason, 
the American Heart Association categorized children with ESRD as a group of patients with the highest 
risk for cardiovascular morbidity in childhood (Kavey et al., 2006). It is worth noting that vascular and 
tissue calcifications, a hallmark of cardiovascular disease in patients with CKD (Mizobuchi et al., 2009), 
result from extensive vascular remodeling and indicate that the pathological process leading to 
cardiovascular mortality is already advanced and may be on its final path. In recent years, there has 
been increasing evidence that changes in the microvasculature in cardiac muscle (Amann & Ritz, 2000; 
Edwards-Richards et al., 2014) and in skeletal muscle (Flisinski et al., 2008) precede the known 
pathological remodeling or deterioration of the macrovasculature, indicating the need for thorough 
investigation of small vessel pathology in uremia model organisms.  
 
Figure 1 Prevalence of cardiovascular comorbidities in ESRD patients by age classes (2013). AFIB: 
atrial fibrillation; AMI: acute myocardial infarction; ASHD: atherosclerotic heart disease; 
CHF: congestive heart failure; CVA/TIA: cerebrovascular accident/transient ischemic attack; 
CVD: cardiovascular disease; PAD: peripheral arterial disease; SCA/VA: sudden cardiac 




1.2 Vessel Development, Maturation, and Maintenance 
1.2.1 Key Factors Affecting the Vascular Structure 
Vascular development, remodeling, and depletion are initiated as microvascular processes. 
Vasculogenesis (i.e., de novo formation of vessels during embryonic development) and angiogenesis 
(i.e., growth of vessels from existing vasculature) are controlled by a complex system of cytokines and 
growth factors (Risau, 1997) as well as by hemodynamic factors, such as blood flow (Kochhan et al., 
2013), hematocrit (He et al., 2008), vascular tone (Lobov et al., 2011, Chen et al., 2012) and shear stress 
(Buschmann et al., 2010). Growth factors inducing angiogenesis, such as bFGF, TGF-α, TGF-β, TNF-α, 
or VEGF, are secreted by endothelial cells and act in an autocrine or paracrine fashion (Folkman, 2006).  
The oxygen level in the tissue is measured by the hypoxia-inducible factor (HIF). HIF acts as a 
heterodimeric transcription factor, binding to specific DNA sequences (hypoxia-responsive elements) 
and can thus regulate a huge number of effector genes, influencing angiogenesis, erythropoiesis, and 
energy metabolism (Armulik et al., 2005).  
The HIF 1 subunit is constitutively expressed in the tissue; in normoxia, HIF 1 rapidly undergoes 
prolyl hydroxylation, binds to the von Hippel-Lindau tumor suppressor protein complex, and is 
degraded in the proteasome. In hypoxia, however, the  subunit escapes prolyl hydroxylation and 
binds to the stable HIF  subunit, forming a functional transcription heterodimer (Kida, 2014). The HIF 
target gene which plays a key role in vessel development, maturation, and remodeling is the vascular 
endothelial growth factor (VEGF) (Senger et al., 1983; Ferrara & Henzel, 1989), as it has been shown 
that hypoxia leads to a profound upregulation of VEGF expression (Shweicki et al., 1992). VEGF plays 
an important role in both vasculogenesis and angiogenesis. Different VEGF types and splice variants 
thereof exist, but VEGF-A (hereinafter simply referred to as VEGF) is the most relevant for vessel fate. 
VEGF initiates the creation of new blood vessels during embryonic development, upon extensive 
exercise, after injury, or to establish collateral circulation to bypass blocked vessels.  
VEGF can bind to two different receptors (VEGFRs): fms-like tyrosine kinase-1 (flt-1), termed VEGFR-1 
(de Vries et al., 1992), and kinase insert domain receptor (KDR, in humans) or fetal liver kinase-1 (flk1, 
in the mouse), termed VEGFR-2 (Terman et al., 1992). VEGFRs are tyrosine kinase receptors which, 
upon ligand binding, dimerize and become activated through transphosphorylation. It has been shown 
that most of the complex angiogenic signaling of VEGF (reviewed by Koch & Claesson-Welsh, 2012) is 
mediated by VEGFR-2. Absolute VEGF concentrations may drive endothelial cell proliferation while 
varying gradients of VEGF isoforms may trigger endothelial cell migration and differentiation 
(Carmeliet et al.
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Additional factors, interacting with VEGF signaling, are angiopoietins. Angiopoietins and their 
receptors form an endothelial-specific signaling system, regulating blood and lymphatic vessel 
development. Angiopoietin 1 (Ang-1) stabilizes the mature blood vasculature and has a role in the 
maturation and remodeling of vessels (Eklund & Olsen, 2006), while Angiopoietin 2 (Ang-2) has pro-
angiogenic or anti-angiogenic effects, depending on the presence of VEGF (Kim et al., 2000). Ang-1 and 
Ang-2 both bind to the same receptor, tunica interna endothelial cell kinase (Tie-2) which acts via the 
anti-apoptotic protein kinase B pathway. The exact mechanism, how the two ligands can transfer 
different effects via Tie-2 remains controversial. Existing data suggest that Ang-1 and Ang-2 interact, 
either directly or by competing for Tie-2 binding sites. Therefore, the Ang-1/Ang-2 ratio determines 
either a pro-angiogenic or anti-angiogenic cellular environment (Maisonpierre et al., 1997). Tie-2 is 
constitutively expressed in endothelial cells and may thus be required for vessel network integrity 
(Eklund & Olsen, 2006). Mutations in the Tie-2 gene can lead to vascular anomalies, such as 
hemangiomas (Wang et al., 2004), while elevated Tie-2 expression in a mouse model may lead to a 
disease mimicking psoriasis (Voskas et al., 2005). In contrast, Tie-1 is an orphan receptor that does not 
bind Ang-1 or Ang-2. Tie-1 may play a role in disease as mediator of inflammation. A recent study 
suggests an interactive model of Tie-1 and Tie-2 function, in which dynamically regulated Tie-1 versus 
Tie-2 expression determines the net positive or negative effect of Tie-1 on Tie-2 signaling (Savant et 
al., 2015). 
1.2.2 Network Formation and Maturation 
The mechanisms for the formation, maturation, and maintenance of vessel networks are still poorly 
understood. Most likely, they follow an overshooting process, where during development an 
abundance of vasculature is formed that requires subsequent trimming of branches and regression of 
individual vessels to achieve a customized network, suiting the needs in respective tissues, locations 
and time (Pries & Secomb, 2014; Korn & Augustin, 2015). This notion is corroborated by the fact that 
unidirectional tumor growth based on an upregulation of proangiogenic factors (Eggert et al., 2000) 
results in chaotropic vasculature which is normalized upon anti-angiogenic treatments (Carmeliet & 
Jain, 2011). Thus, mechanisms of vessel regression or even pruning of larger vessel branches can be 
considered as part of normal vessel network development, maturation, and adaptation. There is 
compelling evidence that apoptosis is a major driver for the regression of microvascular networks (Alon 
et al., 1995). However, other mechanisms that lead to the remodeling or rarefaction of vascular 
networks exist. Endothelial cells of pruned vessels may also migrate and re-integrate into other 
segments of a network (Franco et al., 2015) or de-differentiate in a process known as endothelial to 
mesenchymal transition (Zeisberg et al., 2007). 
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VEGF acts as an important factor for vessel maintenance, as it is constitutively expressed in adult tissue 
(Iliescu et al., 2010) while VEGF signaling depletion leads to vessel regression (Meeson et al., 1999). 
Other pathways involved in keeping the delicate balance between angiogenesis, maintenance and 
regression may be Ang/Tie-2 signaling, acting through phosphoinositide 3-kinase and protein kinase B 
which influences apoptosis, as well as Notch, canonical Wnt and non-canonical Wnt signaling (Phng et 
al., 2009; Korn et al., 2014). Thus, the fate of a network is dependent on the interplay of many factors 
that may either promote vessel maintenance or regression. VEGF, non-canonical Wnt, and blood flow-
induced signaling act as maintenance factors, while Notch and canonical Wnt signaling support vessel 
regression either by hindering vessel stabilization and proliferation or by promoting vessel constriction 
and flow stasis, respectively (Korn & Augustin, 2015). The effect of Ang/Tie-2 signaling depends on the 
prevalence of Ang-1 or Ang-2 (Holash et al., 1999) and, in the latter, on the concentration of VEGF 
present (Lobov et al., 2002). Loss of microvascular homeostasis may result in chronic tissue hypoxia 
and eventually in target organ damage (Lockhart et al., 2009). 
 
1.3 Target Organ Damage in Chronic Kidney Disease 
1.3.1 Inflammation and Fibrosis 
Persistent inflammation is correlated with cardiovascular mortality rates in ESRD patients (Stenvinkel 
et al., 2005). In CKD, inflammation is caused, amongst others, by increased oxidative stress resulting 
from a reduced plasma antioxidant activity (Mimic-Oka et al., 1999) and increased levels of cytokines 
such as IL-1, IL-6, and TNF-α. The kidneys are usually involved in the metabolism and removal of 
modified proteins and protein-associated compounds resulting from oxidative stress. CKD leads to the 
accumulation of these proteins called advanced glycation end products, AGE (Kaysen et al., 2001). AGE, 
however, may activate mononuclear cells (i.e. lymphocytes, monocytes, and macrophages) and thus 
directly spark inflammation. In addition, many other mechanisms contribute to chronic inflammation 
in CKD (Silverstein, 2009). 
Blood leukocytes circulate the vasculature as long as they remain in their quiescent state. Inflammation 
induces leukocyte capture from the blood flow to the vessel wall. Upon rolling along the vessels’ 
endothelium, leukocytes become activated by endothelial cytokines, gradually slowing them down. 
Eventually, leukocyte rolling turns into tight adhesion and diapedesis into the adjacent tissue 
(Sperandio et al., 2006). Adherence of leukocytes to the endothelial surface occurs primarily in 
postcapillary venules and is facilitated by the lower shear stress present in venules compared to 
arterioles (Pries & Secomb, 2008). A local vessel dilatation at the region of inflammation may further 
reduce shear stress (Secomb et al., 2003) and alleviate adherence and subsequent diapedesis.  
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Permanent inflammation affects functional tissue and triggers regeneration processes leading to 
fibroblast activation and subsequent fibrosis. In fibrosis, tissue parenchyma is replaced by connective 
tissue. Fibrosis can be considered as a misguided healing process on the basis of a constant growth 
stimulus which may impede oxygen diffusion, leading to impairment of organ function, and eventually 
to organ failure (Mutsaers et al., 2015).  
1.3.2 Microvascular Rarefaction 
Oxygen and nutritional supply of body tissue is achieved via blood flow in vessels and the diffusion of 
the required substances from the vessels to their target area. Diffusion is effective only over short 
distances and therefore occurs mainly in the dense microvascular networks pervading tissue and organ 
parenchyma. To meet the tissue’s requirements for both flow and diffusion, a highly organized 
network structure of the microvasculature is necessary. The microvasculature consists of small 
resistance arteries, arterioles, capillaries and venules with a diameter below 200 µm which are 
responsible for 70 % to 90 % of the blood pressure regulation. In this study, microvessels were further 
differentiated according to their caliber. Measured vessels were classified into the categories of ≤8 µm, 
>8 to ≤16 µm, >16 to ≤32 µm, >32 to ≤64 µm, >64 to ≤128 µm, and >128 µm, respectively. The low 
solubility of oxygen and the resulting maximum diffusion distance of 20 to 200 µm make network 
density the limiting factor for oxygen supply (Pries & Secomb, 2014).  
Chronic disease conditions can be detrimental to the microvasculature. There is increasing evidence 
indicating that microvascular rarefaction in CKD occurs early in the disease process and that these 
alterations may be subclinical early markers for organ damage (Amann & Ritz, 2000; Edwards-Richards 
et al., 2014; Burkhardt et al., 2016).  
 
1.4 Regulation of Tissue Oxygen Supply 
In the microvasculature, effective oxygen exchange is influenced by physical or functional alterations 
in flow patterns (Pries & Secomb, 2008). The oxygen uptake in tissue is determined by the local vessel 
density, the blood flow, the hematocrit, and the oxygen saturation of the blood’s hemoglobin. Vessel 
density is a crucial parameter that may change over time but which can be considered stable at a given 
point in time. Likewise, the hematocrit can vary but can be assumed to be a systemic parameter that 
is stable and similar in any given part of the body. In contrast, blood flow and oxygen saturation are 
dynamic functional parameters that can adapt more quickly to changing environmental conditions.  
Blood flow through individual arterioles can be regulated locally and is subject to dynamic changes 
depending on shear stress on the vessel endothelium (Bayliss effect), endocrine factors, or nerval 
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influences. As described in Poiseuille’s law (see below), blood flow is dependent on the fourth power 
of vessel diameter, rendering this parameter the single most powerful flow regulator.  
 
where  
V = volume flow 
p = pressure difference between the ends of the vessel 
r = internal radius of the vessel 
η = blood viscosity 
l = length of the vessel 
 
Vessel diameter is controlled by the tone of smooth muscle cells enclosing these vessels. Arterioles 
have a positive tone of their smooth muscles even in the resting state. Changes in tone are achieved 
either through the activity of the endothelial cells lining the vessel interior (endothelium-dependent) 
or the smooth muscle cells surrounding the vessel wall (endothelium-independent).  
Oxygen saturation of the blood hemoglobin is a parameter of pulmonary function. The arterio-venous 
difference in oxygen content (avΔO2) of an afferent arteriole and an efferent venule quantifies which 
oxygen fraction is effectively deposited in a tissue under investigation. A decreased avΔO2 may be the 
result of a decreased microvessel density, a hindered diffusion, or a structural or functional shunt (Pries 
et al., 2010).  
Both vessel tone and avΔO2 are subject to multiple nervous, endocrine, cellular, and hemodynamic 
influences. Hence, for realistic results, they have to be tested in vivo rather than in an artificial in vitro 
environment.  
 
1.5 Animal Models for the Study of Microvasculature in Uremia 
In vivo microscopy of the cremaster muscle is an established skeletal muscle model for the study of 
microvascular networks, as its minor layer thickness renders it translucent and relatively easy to access 
experimentally. For this investigation, the mouse was the preferred model because the 
microvasculature is easily accessible for established in vivo structural and functional studies. Two 
established models for the induction of kidney disease were chosen: a remnant kidney model and 
adenine feeding (Shobeiri et al., 2010). In the remnant kidney model, unilateral nephrectomy and the 
removal of the poles of the remaining kidney (5/6 nephrectomy, 5/6 NX) reliably produces mild chronic 
renal disease (Gabizon et al., 1985). In the adenine model, which was first introduced in rats (Yokozawa 
et al., 1986), adenine is added to the normal diet; intermediate products of the adenine metabolism 
then precipitate in the kidney tubules, leading to severe CKD. The adenine model is associated with 
Poiseuille’s law: V = π p r 4 / 8 η l 
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local and systemic inflammation (Tamura et al., 2009). Both models were used in parallel in this study, 
to exploit the unique features of each approach, namely differences in the severity of inflammation 
and uremia, respectively, and to examine whether the effects of uremia were independent of the 
model.  
CKD is characterized by a decreased glomerular filtration rate which can be monitored by increasing 
blood levels of compounds usually removed from the blood by the healthy kidney. Urea is one of the 
most abundant substances produced by the liver and is usually disposed of in the kidney via renal urine 
production. Urea, however, is only one of a plethora of compounds accumulating in the blood of CKD 
patients, of which many are not yet identified or of which the individual contributions to the 
accompanying disease process are not clear. The term ‘uremia’ is therefore used to generally describe 
symptoms accompanying kidney failure which are thought to be largely due to the accumulation of 
waste products in the blood such as urea and creatinine (Meyer & Hostetter, 2007). Symptoms of 
uremia are variable and non-specific and in humans include headache, fatigue, seizures, serositis, 
nausea, pruritus, peripheral neuropathy, sexual dysfunction, bone disease with fractures, and weight 
loss. Excessive uremia may lead to encephalopathy, coma, and eventually, death. 
No specific values for urea and creatinine demarcate the onset of uremia. In this study, uremia was 
classified according to blood urea levels as mild, if treated animals developed a urea blood level of up 




1.6 Aims of this Study 
There is convincing evidence that CKD is accompanied physiologically with structural and functional 
changes in the microvasculature. Clinically, CKD is associated with a highly increased risk of cardiac 
mortality, which is particularly pronounced in the young, where cardiovascular events are usually rare. 
It is, however, currently unknown whether the functional changes in the microvasculature precede 
cardiovascular disease. Moreover, we do not yet know which factors trigger these changes, eventually 
leading to a pathological dysregulation of tissue homeostasis. Therefore, the goals of this study are the 
characterization of functional disturbances of the microcirculation in uremic animals as model 
organisms for CKD:  
1. Generate mild to severe uremia in two established animal models of CKD.  
2. Characterize in vivo the dose-dependent functional impact of uremia on skeletal muscle 
vasculature. 
3. Compare the skeletal muscle vasculature of CKD mice determined in vivo with cardiac muscle 
vasculature of the same animals analyzed post mortem. 
4. Determine the chronological order of microvascular and macrovascular changes to provide 
diagnostic indications for an early identification of myocardial changes in CKD.  
5. Analyze transcriptional changes in the myocardium of uremic animals as explanatory approach for 





2 Material and Methods  
2.1 Laboratory Animals 
In vivo studies were performed on the microvascular network of the cremaster muscle of BALB/c mice. 
A total of 39 six-week-old male BALB/c mice with a weight of 17 to 25 g were obtained from Charles 
River GmbH (Sulzfeld, Germany). The animals were kept in facilities with stable environmental 
conditions and a twelve-hour artificial light day and night cycle. While all animals underwent intravital 
microscopy for microvessel density measurement in a separate study (Prommer, 2018), a varying 
number of animals was employed for further functional analyses. The exact number of animals 
employed in these individual experiments are given in the respective chapters. All animal experiments 
were performed in accordance with institutional guidelines for animal care and use and were approved 
by the Institutional Animal Care and Use Committee and the local State Office of Occupational Health 
and Technical Safety (Landesamt für Gesundheit und Soziales, Berlin, reference: G 0396/10). 
 
2.2 Uremia Induction 
Experimental uremia was induced by either adenine feeding or subtotal nephrectomy (5/6 NX) 
(Prommer et al., 2018). Adenine-induced uremia was deployed as follows: For a period of four weeks, 
19 mice received a ROD 18 complete diet for breeding and maintenance of mice (LASvendi, Soest, 
Germany) including 0.2 % adenine additive (Sigma-Aldrich, St. Louis, USA) ad libidum. Eight control 
mice received ROD 18 diet without additives. Intravital microscopy was performed after four weeks in 
all animals.  
In the 5/6 NX model, uremia was induced via a two-stage surgical procedure in 7 mice. Thirty minutes 
prior to surgery, animals received preoperative analgesia (metamizol, 200 mg/kg p.o.). Animals were 
anaesthetized with isoflurane (4 %/L O2 for induction of anesthesia, and 1.5 % to 2.0 %/L O2 for 
maintenance of anesthesia). The left flank was shaved and disinfected. The skin was cut and the 
muscles severed. The left kidney was removed completely and the left ureter, renal artery and vein 
were ligated. The abdominal cavity was closed using absorbable suture material. After a two-week 
recovery period, the above analgesia, anesthesia procedure, and surgical access was repeated on the 
right side. The right renal artery and vein were freed and clipped. About 1/3 of the anterior and 
posterior kidney pole and from the cortex opposite the kidney’s hilus were removed with an H-shaped 
cut, sparing the renal pelvis. The vessel clamps were removed for a few seconds to allow bleeding and 
subsequent coagulation. After a short period of repeated ischemia, clamps were finally removed. 
Wound management was conducted as described above.  
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In 5 sham-operated animals, the same two-stage surgical procedure was applied. The respective 
kidneys, however, were just exposed and shifted to provide comparable operative stress. Post-surgery, 
all animals received tramal 10 mg/kg s.c. and subsequently tramal 2.5 mg/100 mL for three days via 
their drinking water ad libidum. After surgery, the animals were kept under standardized housing 
conditions for a period of 4 months before the start of the intravital microscopy analysis. Body weight 
was monitored on a daily basis.  
 
2.3 Cremaster Preparation 
Mice were anesthetized intraperitoneally with urethan i.p. (1,500 mg/kg), and ketamine i.m. (50 
mg/kg), placed on a heating mat system equipped with a thermal sensor (Harvard Apparatus, 
Cambridge, UK) and fixed on a 29 cm x 28 cm acrylic glass stage in dorsal position. During surgery or 
intravital microscopy, anesthesia was continuously monitored upon pedal withdrawal reflex. 
Appropriately, ketamine was replenished i.p. (half dose of initial anesthetic). All animals underwent 
tracheotomy to prevent airway obstruction, catheterization of the right jugular vein for infusion of 0.9 
% NaCl to maintain fluid balance as well as catheterization of the left carotid artery for continuous 
arterial blood pressure and heart rate monitoring. Cremaster preparation followed a modified protocol 
of Hill et al. (1990). The scrotum was cut, the cremaster muscle exposed and fascia and connective 
tissue were cautiously removed. The cremaster was mounted on the acrylic glass stage to a surface of 
about 1 cm² and covered with transparent film (Saran, SC Johnson, Racine, USA) to minimize 
evaporation. The muscle tissue was regularly moistened using 37°C tempered 0.9 % NaCl solution. 
After completion of the experiment, pentobarbital i.p. (250 mg/kg) was administered. 
 
2.4 Intravital Microscopy 
The cremaster muscle’s microvasculature was visualized with a modified intravital microscope 
(Axiotech vario, Carl Zeiss, Jena, Germany) applying a saline immersion objective (20x/NA 0.17) and a 
1.6x microscope optical path amplification (Ley et al., 1987). A Xenon AC 100 V lamp equipped with 
transmitting optical fibers (Leitz, Wetzlar, Germany) was employed as a light source. Light intensity 
was reduced to prevent tissue damage by employing a green filter (Schott, Mainz, Germany) which 
also increased contrast between erythrocyte-filled vessels and tissue background. A one-minute 
sequence of blood stream in the vessels was recorded on videotape using a CCD (charge coupled 
device) camera system (Kappa Optronics GmbH, Gleichen, Germany) connected to a VHS recorder 
(DVCAM 64 PDV-64ME, Sony, Japan) and overlaid with a video timer signal (VTG33, FOR-A, Japan). In 
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this film, vessels, blood streams, and for small vessels, the movement of individual erythrocytes or 
leukocytes was clearly visualized.  
 
 
Figure 2: Experimental setup for intravital microscopy and functional analyses. Anaesthetized 
animals with dissected cremaster muscle were placed under the microscope equipped with 
different light paths for transillumination or reflected light, and an X/Y/Z positioning table 
for reproducible access of distinct positions within the specimen. The system can be 
equipped with various cameras, depending on the application. The microscopic visual field 
can be viewed on a video screen and recorded simultaneously. A peristaltic pump provides 
an even application of buffer/chemicals to the cremaster muscle. The microperfusion pump 
used for administration of vasodilatory substances is not visible in this image.  
 
The exact positioning of the fixed cremaster tissue was achieved using a digital X/Y/Z positioning 
microscopy table (Elesta Elektrotechnik AG, Bad Ragaz, Switzerland). To visualize vessel density in 
experimental animals, a position adjacent to the first bifurcation of the largest efferent vessels of the 
cremaster muscle was selected as a starting point for the recordings. An initial visual field of 350 μm x 
250 μm muscle tissue area was recorded followed by further visual fields resulting in a 3x3 matrix area 
(9 visual fields, termed cremaster areas) of approximately 1,050 x 750 μm (neighboring visual fields 
overlap about 10 %). In total, up to 5 cremaster areas per animal were recorded, corresponding to up 
to 45 visual fields. Distances between distinct cremaster areas were 1,720 μm horizontally and 
2,020 μm vertically.  
For analyses of leukocyte rolling velocity, avΔO2, and vascular tone, intravital microscopy was 















software (Vision 3D) allowing for the retracing of vessel distribution, vessel segment lengths, 
bifurcations, and vessel diameter (Pries, 1988).  
 
2.5 Determination of Leukocyte Rolling Velocity 
In the video recordings described above, rolling leukocytes could be readily identified in venules 
without additional staining. The distances covered by individual leukocytes could be measured exactly 
using the Vision 3D image analysis software (Pries, 1988). The corresponding time was determined and 
the velocity calculated by metering the overlaid video timer signal. Multiple data points were used to 
assess the mean leukocyte rolling velocity in the respective animals.  
 
2.6 Vascular Oxygen Saturation Imaging Spectroscopy  
Oxygen saturation in cremaster muscle microvessels was assessed by using an imaging spectroscopy 
approach (Styp-Rekowska et al., 2007), taking advantage of changes in the hemoglobin absorption 
spectrum according to its oxygen saturation (Zijlstra et al., 1983). Feeding arterioles of a tissue area 
and the draining venules running in parallel were analyzed in an intravital microscopy visual field of 
350 µm x 250 µm. The fixed cremaster muscle was transilluminated with a spectrum of 50 consecutive 
wavelengths, evenly spaced in 2 nm steps from 500 to 598 nm, provided by a monochromator 
(Polychrome IV LPS150, TILL Photonics, Gräfeling, Germany). Brightness was adjusted using a grey filter 
(Schott, Mainz, Germany). Each exposure to a certain wavelength was recorded in a distinct image, 
resulting in a stack of images of the same motif for spectral analysis (monochromator and digital 
camera are part of an imaging system from TILL Photonics, Gräfeling, Germany). Light intensities were 
converted into integer data with a resolution of 4095 discrete values by the software of the imaging 
system (TILL Vision, TILL Photonics, Gräfeling, Germany). For the calculation of oxygen saturation, a 
dedicated software was used (SOAP - Saturation of Oxygen Analysis Program, Styp-Rekowska et al., 
2007). Optical densities for a given wavelength were analyzed for each pixel, subtracting background 
intensities and calculating the amounts of hemoglobin and oxyhemoglobin after calibration with 
appropriate reference absorption spectra. The program includes a Fourier algorithm for movement 
correction, eliminating artifacts due to muscle contraction or breathing. This approach offers 
simultaneous measurement of the hematocrit levels in individual vessels.  
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Figure 3: Spectroscopic avΔO2 determination. Sample image from a uremic mouse illustrating the 
spectroscopic methodology for avΔO2 determination. An artery with a bifurcation is 
depicted on the left, the adjacent vein is shown on the right. Flow directions are indicated 
by black arrows. Scalebar: the double arrow equals 100 µm. Due to a background 
correction, vessels are clearly singled out from the tissue background. The mean O2 
saturation value is 94.6 % for the artery and 81.5 % for the vein. Color coding is given on 
the right scale bar on a spectrum from deep purple (0 % O2 saturation) to bright red (100 % 
O2 saturation). 
 
2.7 Measurement of Vascular Tone 
Arterial vessels display a distinct resting tone, enabling the organism to quickly adjust blood pressure 
and regional blood supply according to the actual need. To achieve a complete relaxation of the 
vessels’ smooth muscles, a mixture of endothelium-dependent (acetylcholine) and endothelium-
independent vasodilatory compounds (adenosine, papaverine, sodium nitroprusside) was applied to 
the cremaster muscle preparation. This treatment can attain up to 95 % of the maximum vessel 
dilatation (Klotz et al., 1995). In endothelial cells, acetylcholine triggers a receptor-mediated 
vasodilatation by inducing the endothelial NO synthetase (eNOS) via muscarinic receptors. The 
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produced NO diffuses to the smooth muscle cells and leads to vasodilatation. Adenosine, papaverine 
and sodium nitroprusside act in an endothelium-independent fashion by a direct dilating effect on the 
smooth muscle cells. Adenosine binds to A2-receptors which belong to the G protein-coupled receptor 
family. A2 receptor activation leads to an increase of intracellular cAMP levels. Papaverine acts as a 
PDE inhibitor thus also increasing intracellular cAMP concentrations. Sodium nitroprusside acts as a 
direct NO donor in smooth muscle cells.  
The vascular tone measurement was performed with the intravital microscopy setup as described 
above, focusing on cremaster arterioles. The buffered superfusion fluid (Duling & Staples, 1976) of 
131.9 mM NaCl, 4.7 mM KCI, 2.0 mM CaCl2, 1.2 mM MgS04, and 18 mM NaHCO3 was preheated to 37°C 
and aerated with 95 % N2 and 5 % CO2 to maintain a pH of 7.35. The tissue-covering film was removed 
and the fixed muscle was immediately sprinkled with superfusion fluid for 5 min using a peristaltic 
pump (Tokyo Rikakikai, Tokyo, Japan) before adding a cocktail of vasodilatory compounds of 0.01 mM 
acetylcholine (Sigma-Aldrich, St. Louis, USA), 10 mM adenosine (Serva GmbH, Heidelberg, Germany), 
0.2 mM papaverine (Sigma-Aldrich, St. Louis, USA), 0.01 mM sodium nitroprusside (Sigma-Aldrich, St. 
Louis, USA) to the superfusion fluid via a microperfusion pump (Harvard Apparatus Ltd., Edenbridge, 
UK). Images of the vessels were recorded from identical positions using a digital X/Y/Z positioning 
microscopy table (Elesta Elektrotechnik AG, Switzerland) before and after administering the 
vasodilatory cocktail for 5 min.  
The Vision 3D image analysis software (Pries, 1988) was used to determine the vessel diameter by 
dropping a perpendicular line between the limiting vessel walls. Since the inner endothelial layer of 
the vessels was clearly distinguishable from the vascular lumen in each recording, the vessel diameter 
could be precisely determined. To calculate the arterial tone, the ratio of the difference between 
arterial diameter of maximal relaxation Dmax and arterial diameter at resting state D divided by Dmax 




2.8 Blood and Tissue Sample Handling 
Following the intravital microscopy analysis, blood samples were drawn for further analyses of serum 
urea, creatinine, and IL-6 levels. Blood was stored at room temperature for 30 min, centrifuged at 4°C 
and the supernatant was frozen and stored at -80°C until further use. Urea and creatinine were 
analysed by ‘Labor Berlin’ of the Charité Universitätsmedizin Berlin, following standardized protocols. 
Tone [%] = 
max  
max
 x 100 
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IL-6 levels were determined using an ELISA test kit with pre-coated plates (BioLegend, Fell, Germany). 
Moreover, heart, kidneys, aorta, and extensor digitorum longum muscle were harvested. Organs were 
dissected into 3 portions. One specimen was immediately frozen in liquid nitrogen and stored at -80°C, 
the remainder was preserved in phosphate-buffered formaldehyde solution 4 % (Roth GmbH, 
Karlsruhe, Germany) for subsequent paraffin-embedding. Paraffin blocks were sliced in 4 µm or 8 µm 
layers using a microtome (Leica, Wetzlar, Germany). Hematoxylin-eosin staining with hemalm and 
eosin (Roth GmbH, Karlsruhe, Germany) and von Kossa staining with sodium thiosulfate (Fluka, Buchs, 
Switzerland) and silver nitrate (Merck, Darmstadt, Germany) were performed using standard 
protocols. The intima-media thickness (IMT) of mouse aortas was measured using representative von 
Kossa-stained paraffin-embedded sections. Using the open source program Image J, the distance from 
the lumen-intima edge to the media-adventitia edge of the arteries was measured at 12 different spots 
per section. The average mean of these segments was taken as mean IMT±SD. 
 
2.9 Immunohistochemistry 
Immunohistochemistry was performed on formalin-fixed tissue sections according to standard 
methods. Dewaxed and rehydrated tissue sections were incubated in 3 % hydrogen peroxide to block 
endogenous peroxidases. The heat-induced antigen retrieval was performed in a pressure cooker, 
using the Dako REAL Target Retrieval Buffer (Dako Cytomation, Glostrup, Denmark). Monoclonal 
antibodies against Mouse CD31 (1:100) (PECAM-1) (D8V9E) XP Rabbit mAb were purchased from Cell 
Signaling, Beverly, MA, USA. Bound antibodies were visualized with the Vector NovaRED detection kit 
(Vector Laboratories, Burlingame, CA, USA). Cell nuclei were counterstained with hematoxylin and 
eosin and antibody diluents without primary antibodies were used as respective negative controls. 
 
2.10 Gene Expression Analysis by qPCR 
Gene expression levels in murine heart tissue were determined by quantitative real-time reverse 
transcription polymerase chain reaction (RT-PCR). Cryo-conserved heart tissues from mice with mild 
(n = 10) or severe uremia (n = 6) and controls (n = 13, thereof 8 adenine controls and 5 sham-operated 
controls) were minced in Trizol (Invitrogen, Karlsruhe, Germany) and RNA was isolated according to 
the manufacturer’s protocol, treated with DNase to remove genomic contaminations, and further 
purified using RNeasy columns (Qiagen, Hilden, Germany). RNA was transcribed into cDNA with the 
High Capacity RNA to DNA kit (Applied Biosystems, Foster City, CA, USA) and cDNA concentrations 
were determined by a NanoDrop ND-1000 device (NanoDrop Technologies, Wilmington, NC, USA). 
Quantitative PCR using SYBR Green Master Mix (Applied Biosystems, Foster City, CA, USA) and 
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subsequent melting curve analysis was performed using the Mx3000p system (Agilent Technologies, 
Waldbronn, Germany). Relative RNA amounts were calculated using the 2−ΔΔCt method (Livak & 
Schmittgen, 2001) and normalized to mean mRNA expressions of the housekeeping genes YWHAZ 
(tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide) and 
HPRT1 (hypoxanthine-phophoribosyl transferase). The sequences of the primers (BioTez GmbH, Berlin, 
Germany) are given in table 2.  
Table 2: Forward and reverse primers used for RT-PCR in the cardiac muscle to determine the 
quantitative expression of genes involved in angiogenesis 
Gene Forward primer Reverse primer 
HIF 1α 5'-TCATCAGTTGCCACTTCCCCAC-3' 5'-CCGTCATCTGTTAGCACCATCAC-3' 
VEGF 5'-ACTTGTGTTGGGAGGAGGATGTC-3' 5'-AATGGGTTTGTCGTGTTTCTGG-3' 
VEGFR-2 5'-TTCCCCCCTGGAAATCCT-3' 5'-ACAGACCCGGCCAAACAA-3' 
Ang-1 5'-AACCTCACCCTGCAAAGATG-3' 5'-CACAGATGGCCTTGATGTTG-3' 
Ang-2 5'-CAAGGCACTGAGAGACAC-3' 5'-TGCGCTTCAGTCTGGTACAC-3' 
Tie-1 5'-GTGCCACCATTTTGACACTG-3' 5'-CAGGCACAGCAGGTTGTAGA-3' 
Tie-2 5'-GATTTTGGATTGTCCCGAGGTCAAG-3' 5'-CACCAATATCTGGGCAAATGATGG-3' 
MMP-2 5'-AAAGGACTCGGGTTGTCTGA-3' 5'-ACTTGGTTCTCCTCCATCCA-3' 
MMP-9 5'-TCCCGAGAGTCCAACTCACT-3' 5'- CATCTCACCTGGAGGACACA -3' 
 
2.11 Study Organization 
Experiments were performed to study either functional alterations of the microvasculature (as 
documented in this doctoral thesis) or, in a separate study, structural changes of the microvasculature 
(Prommer, 2018). Structural findings (Prommer, 2018) and functional findings (this study) were derived 
from identical animals, thus providing a comprehensive, coherent data set. The angioarchitecture of 
the microvasculature as described by structural measurement during the intravital microscopy 
experiments of all animals provided the basis for further data analyses and interpretation. The 
successive functional analyses could often be deduced only from subsets of animals due to a limitation 
of the overall experimental time, complexity of the respective experimental set-up, possible corruption 
of subsequent data due to the application of compounds, or stress. Therefore, numbers of animals 
given in the following chapters represent the quantity of animals successfully investigated in the 
respective experiments rather than the total number of experimental animals.  
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2.12 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 5.01 (GraphPad, La Jolla, CA, U.S.A.). 
Numerical values were documented as mean ± standard deviation (SD). Whiskers of boxplot graphs 
show the standard error of the mean (SEM). The Mann-Whitney test was used to test if two 
independent samples of observations were drawn from the same distribution, applying a significance 
threshold of p < 0.05. Linear regression of a population was calculated by minimizing the accumulated 
squares of the residuals (least squares method). The confidence interval represents the range where 
the true mean exists with a probability > 95 %. The Pearson correlation coefficient r was used as a 
measure of the linear correlation between two variables. Values between 0.3 and -0.3 were considered 





3.1 Two Experimental Procedures Generate CKD/Uremia of Different Severity 
3.1.1 Serum Urea Levels 
Both methods employed, adenine feeding and 5/6 NX, led to uremia by destruction of the renal 
parenchyma. The severity of CKD was assessed by the serum urea level rather than the serum 
creatinine level, as in mice serum creatinine elevation following renal injury is delayed if compared to 
serum urea; the increase is less pronounced and is dependent on body mass, which diminishes in the 
adenine model depending on the adenine concentration of the diet and duration of feeding. (Tamura 
et al., 2009; Oyama et al., 2010). The level of uremia achieved was variable within respective 
experimental groups, permitting the investigation of the effect of CKD of different severity on the 
microcirculation. A four-week 0.2 % adenine diet led to serum urea levels of 39 to 475 mg/dL (median 
167 mg/dL). In contrast, 5/6 NX followed by a four-month uremia-inducing period led to serum urea 
levels of 57 to 249 mg/dL (median 62 mg/dL). For adenine controls and sham-operated mice, the serum 
urea level was in the range of 21 to 91 mg/dL and 28 to 56 mg/dL, respectively. For stratification, a 
mildly uremic range (up to 250 mg/dL) and a severely uremic range (250 to 475 mg/dL serum urea) for 
treated animals was defined. In general, 5/6 NX led to a mild uremia only while adenine feeding on 
average generated much higher urea levels (7 severe, 12 mild).  
3.1.2 Serum Creatinine Levels 
In the adenine group, control animals (n = 4, as not all of the 8 samples could be successfully analyzed) 
showed a serum creatinine level of 0.18 ± 0.02 mg/dL, in mildly uremic animals (n = 6) the values were 
0.23 ± 0.10 mg/dL (p = 0.25), and in severely uremic animals (n = 7) they were 0.67 ± 0.34 mg/dL (p = 
0.033). In the 5/6 NX group, sham-operated animals (n = 5) showed a serum creatinine level of 0.15 ± 
0.03 mg/dL and in 5/6 NX mice (n = 7) the values were 0.98 ± 1.08 mg/dL (p = 0.087).  
3.1.3 Body Weight 
Weight loss was observed in adenine-induced uremia. The average animals’ body weight at the start 
of the experiment was 22.6 ± 2.2 g. With adenine feeding, body weight decreased by 2 % ± 9 % for 
mildly uremic mice and 19 % ± 7 % for severely uremic mice, respectively, whereas controls increased 
their body weight by 9 % ± 4 %, sham-operated mice by 21 % ± 2 %, and 5/6 NX mice by 14 % ± 11 %. 
Weight at the time of cremaster surgery was significantly associated with serum urea levels (r = -0.33; 
p = 0.039), but not significantly different between uremic groups and their respective controls. The 
serum urea levels were correlated with relative weight loss in both the adenine-fed mice (r = -0.72; p 
= 0.0006) and in the 5/6 NX mice (r = -0.94; p < 0.0001).  
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3.1.4 Serum Interleukin-6 Levels 
Interleukin-6 (IL-6), a marker of inflammation, was significantly elevated in adenine-fed mice with mild 
uremia (900 pg/mL ± 251 pg/mL; p = 0.032, n = 5) and severe uremia (1199 pg/mL ± 261 pg/mL, p = 
0.005, n = 7) compared to controls (516 pg/mL ± 232 pg/mL, n = 5). 5/6 NX mice (n = 7) showed an IL-
6 level of 767 pg/mL ± 595 pg/mL compared to sham-operated controls (593 pg/mL ± 662 pg/mL, n = 
4). The difference was not significant in the 5/6 NX model (p = 0.79). The levels of IL-6 were significantly 
correlated with serum urea levels (r = 0.47; p = 0.012, n = 28, figure 4) but not significantly different 
between groups (p = 0.06). In mice with adenine-induced uremia, but not in 5/6NX animals, IL-6 levels 
were significantly associated with relative weight change (r = -0.41; p = 0.030). 
Figure 4: Correlation of serum IL-6 levels and serum urea levels. The linear correlation analysis 
revealed a significant association of IL-6 serum levels to urea serum levels in experimental 
animals (p = 0.012; r = 0.47, n = 28). The regression line is shown in green, the 95 % 
confidence intervals are given by the two red dashed curves on either side of the regression 
line. Each square represents a data pair measured for individual experimental animals. 
 
3.1.5 Hematocrit Levels 
Hematocrit in arterioles was 0.440 ± 0.043 in controls of the adenine model (n = 8) and 0.355 ± 0.064 
in severely uremic animals (n = 7) of the adenine model (p = 0.005). Differences between controls and 
mildly uremic mice were significant neither in the adenine model (n = 12, p = 0.67) nor in the 5/6 NX 
(n = 5 for sham-operated animals and n = 7 for 5/6 NX animals) (p = 0.79). Hematocrit levels were 
negatively associated with serum urea (r = -0.42; p = 0.008), but not significantly different between 
uremic groups vs. their respective controls.  
 















3.1.6 Mean Arterial Blood Pressure  
The range of mean arterial blood pressure (MAP) was similar in all groups. Mean MAP was, however, 
significantly higher in the severely uremic group of the adenine model (79.1  2.7 mmHg, n = 7) 
compared to their respective controls (73.1  2.8 mmHg, n = 8) (p = 0.0054), but not different between 
mildly uremic animals of the adenine group (n = 12) and their controls (p = 0.070), and 5/6 NX animals 
(n = 7) and their sham-operated controls (n = 5) (p = 0.15).  
 
3.2 Leukocyte Rolling Velocity in CKD 
Leukocyte rolling reflects the direct interaction of leukocytes with the venous endothelial cell layer and 
is a strong indicator of inflammation. As significantly raised IL-6 levels would suggest systemic 
inflammation, leukocyte rolling velocity was tested against parameters found to be altered in uremic 
animals. Leukocyte rolling velocity in the microcirculation depends on the vessel caliber (Prommer, 
2018). In order to allow comparability amongst groups, leukocyte rolling velocity was measured only 
in vessel caliber sizes >64 to ≤128 µm. In no instance, however, could the leukocyte rolling velocity be 
significantly correlated to any parameter tested. Leukocyte rolling velocity was associated neither with 
changes in serum urea concentrations (n = 32, p = 0.84, r = -0.038, figure 5), nor with microvascular 
density in cremaster muscle (n = 32, p = 0.42, r = 0.15, figure 6), nor IL-6 levels (n = 24, p = 0.69, r = 
0.087, figure 7). 
Figure 5: Linear correlation analysis of leukocyte rolling velocity and serum urea levels. No 
significant correlation between serum urea levels and leukocyte rolling velocity in venules 
>64 to ≤128 µm was detected (p = 0.84, r = -0.038, n = 32). Designations of the diagram as 
described in figure 4. 































Figure 6: Linear correlation analysis of leukocyte rolling velocity and microvascular density in the 
cremaster muscle. No significant correlation between microvascular density in venules >64 
to ≤128 µm and leukocyte rolling velocity was detectable (p = 0.42, r = 0.15, n = 32). 
Designations of the diagram as described in figure 4. 
 
Figure 7: Linear correlation analysis of leukocyte rolling velocity and serum IL-6 levels. Although IL6 
levels were significantly elevated in severely uremic animals of the adenine model, IL-6 
serum levels were not correlated with leukocyte rolling velocity in venules >64 to ≤128 µm 
(p = 0.69, r = 0.087, n = 24). Designations of the diagram as described in figure 4. 































































3.3 Changes in Arterial-Venous Oxygen Saturation Difference 
The avΔO₂ is one of the drivers for oxygen uptake in skeletal muscle. To determine the effect on 
peripheral oxygen uptake, the avΔO₂ in microvessels of caliber >64 to ≤128 µm in 14 mice (8 uremic, 6 
controls) was measured. In total, 198 measuring points from 33 vessels were included in the analysis. 
The avΔO₂ of control mice (adenine model) was 20.6 % ± 1.5 %, of sham-operated mice 18.1 % ± 2.4 %. 
5/6 NX mice had a mean avΔO₂ of 12.1 ± 2.9 % (p = 0.0095 vs. sham), adenine-treated mice with mild 
uremia 18.0 ± 1.5 % (p = 0.0635 vs. controls) and mice with severe uremia 15.6 ± 4.3 (p = 0.042 vs. 
controls). Therefore, the avΔO₂ was significantly diminished in both models of CKD, (p < 0.0001, r =  
-0.87, figure 8).  
Figure 8: Linear correlation analysis of arterial-venous difference of oxygen saturation versus 
serum urea levels. Designations of the diagram as described in figure 4. The linear 
correlation analysis showed an inversely proportional relationship of avΔO2 in microvessels 
of caliber >64 to ≤128 µm and serum urea levels (p < 0.0001, r = -0.87, n = 18), suggesting 
a decreased tissue oxygen unload in uremia.  
 
3.4 Control of Vascular Tone  
Change in the efficiency to adjust vascular tone was investigated in arterioles of the adenine model. 
The relative arterial diameter increase in control mice (n = 4) after administering acetylcholine, 
adenosine, papaverine, and sodium nitroprusside as previously described (Klotz et al., 1995) was 15.8 
± 1.5 %. Mildly uremic mice (n = 5) showed a relaxation of 13.2 ± 2.5 % (p = 0.33 vs. controls), while 
severely uremic mice (n = 6) showed 8.7 ± 3.6 % relaxation (p = 0.019 vs. controls). Diameter change 
of arterioles was reduced by 17 % in mice with mild uremia and by 45 % in severely uremic animals  
 
















Figure 9: Vascular tone depending on uremia grade. Vascular diameter was measured as difference 
of vascular diameter before and 5 min after administering vasodilatory substances in 
controls (n = 4), mildly uremic mice (n = 5), and severely uremic mice (n = 6). Tone was 
calculated by percentage increase in vessel diameter, as described in the equation given in 
section 2.7. Severely uremic mice showed a significantly reduced vascular tone (* p = 0.019) 
when compared to controls.  
 
Figure 10: Linear correlation analysis of vascular tone and serum urea levels. Vessel diameter was 
measured at t = 0 min and t = 5 min after application of endothelium-dependent and 
endothelium-independent vasodilators. Tone was calculated by percentage increase in 
vessel diameter, as described in the equation given in section 2.7. The maximum change in 
vessel diameters upon application of vasodilators correlated inversely with the serum urea 
levels (p = 0.001, r = -0.76, n = 15). Designations of the diagram as described in figure 4.  











































if compared to controls (figure 9). The change in vessel diameters correlated inversely with serum urea 
levels (p = 0.001, r = -0.76, figure 10). Thus, severity of uremia was associated with a diminished 
vascular tone. The avΔO2, quantified in some animals that also underwent measurement of vascular 
diameter (n = 10), is strongly linked to the change in vascular tone (p = 0.0024, r = 0.84, figure 11). 
Figure 11: Linear correlation analysis of arterial-venous difference of oxygen saturation and vessel 
tone. To determine the vascular tone, vessel diameter was measured in an intravital 
microscopy setup at t = 0 min and t = 5 min after application of endothelium-dependent 
and endothelium-independent vasodilators. Tone was calculated by percentage increase in 
vessel diameter, as described in the equation given in section 2.7. Although this analysis 
could only be performed for a limited number of animals (n = 10), where avΔO2 as well as 
vascular tone was measured, a strong correlation between the avΔO2 and vascular tone was 
detected (p = 0.0024, r = 0.84). Designations of the diagram as described in figure 4. 
 
3.5 Microvascular Rarefaction in Cardiac Muscle Parallels Rarefaction in 
Skeletal Muscle 
In the cremaster muscle, microvessel density (measured as µm/1000µm2) in the intravital microscopy 
analysis correlated significantly with serum urea levels, independently of the experimental model 
(Prommer, 2018). Using an immuno-histochemistry approach on the formalin-fixed heart specimen 
derived from the same animals used for intravital microscopy, a one-to-one verification was achieved. 
CD31 staining of cardiac muscle revealed a significant decrease in vessel density in uremic mice 
compared to controls. To diminish bias in the visual analysis of CD31 immuno-histochemical staining, 
the evaluation of images was performed by a trained third person. Controls (n = 8) were compared to 
mildly uremic (n = 3, p = 0.012) and severely uremic mice (n = 6, p = 0.0007), thus showing a highly 















significant dose-dependent association (figure 12). There was a close correlation of cardiac microvessel 
density with serum urea levels (p < 0.0022, r = -0.73, figure 13) and with capillary density in the skeletal 
cremaster muscle (p < 0.0001, r = 0.90, figure 14).  
Figure 12: Microvessel density in myocardium as a function of severity of uremia. Microvessel 
density in the myocardium was measured by CD31 immuno-histochemical staining in 
controls (n = 8), mildly uremic mice (n = 3) and severely uremic mice (n = 6). Microvascular 
density was significantly reduced in both mildly (*p = 0.012) and severely uremic animals 
(**p = 0.0007) if compared to controls.  
Figure 13: Linear correlation analysis of microvessel density in the myocardium and serum urea 
levels. The myocardial microvessel density as measured by post mortem CD31 immuno-
staining in cardiac muscle of experimental mice was inversely correlated to serum urea 
levels (p < 0.0022, r = -0.73, n = 17). Designations of the diagram as described in figure 4. 




















































































Figure 14: Linear correlation analysis of microvessel density in the myocardium and microvessel 
density in the cremaster muscle. The myocardial microvessel density was closely correlated 
to microvessel density in the skeletal cremaster muscle (p < 0.0001, r = 0.90, n = 17). 
Designations of the diagram as described in figure 4. 
 
3.6 Microvascular Rarefaction Precedes Visible Macrovascular Pathology 
Capillary density in the cremaster muscle and in the myocardium was significantly reduced in mice 
with CKD. On cross sections of the aorta (figure 15) of controls and severely uremic mice, the vessel 
wall layers (endothelium, internal and external elastic membrane, adventitia layer) could be clearly  
 
 
Figure 15: Arterial cross sections from severely uremic mice and controls do not show any discernible 
differences. Arterial cross sections from uremic animals do not show pathological 
endothelial alterations. (A) Von Kossa staining of the aorta from a control mouse and (B) a 
severely uremic mouse to detect aortal calcification. (C) Severely calcified mouse aorta 
(from a different experiment, photograph courtesy of Veronika Bobb) as a positive control. 
No significant difference and no signs of arteriosclerotic changes are detectable in the 















































A B C 
33 
distinguished. Two tissue sections were evaluated for each animal (n = 19, 11 uremic, 8 controls). All 
animals, including severely uremic mice, showed normal morphology by light microscopy and no 
calcium deposits by von Kossa staining (figure 15 A and B). The intima-media thickness of aortas was 
not significantly different in uremic mice and controls (48.1 + 7.4 vs. 43.6 + 7.1 µm; p = 0.10). 
 
3.7 Dysfunctional Angiogenesis in the Myocardium in Uremic Animals 
To elucidate whether renal impairment, measured by elevated blood urea levels, has an effect on the 
expression of genes in the heart, quantitative RT-PCR on RNA from snap-frozen heart tissue of uremic 
and control animals (adenine controls and sham) was performed. A focus was set on genes known to 
be involved in oxygen level measurement, vessel growth and integrity control: HIF 1, VEGF and its 
receptor VEGFR-2, Ang-1 and Ang-2 as well as their receptor Tie-2, orphan receptor Tie-1, and finally 
matrix metalloproteases MMP-2 and MMP-9. For clarity and to facilitate interpretation, the results of 
the expression analyses are summarized in table 3 at the end of this chapter. 
3.7.1 HIF 1 Expression in Myocardium is Negatively Correlated to Urea Levels 
HIF 1 as a general oxygen sensor of all tissues is of particular interest as it controls the expression of 
an abundance of effector genes. Therefore, changes in the expression of HIF 1 may trigger expression 
changes of other genes.  
HIF 1 expression levels in the heart were negatively correlated to the urea levels in the blood (figure 
16). Controls (n = 13) showed a significantly higher HIF 1 mRNA level than severely uremic mice (n = 
6). For severe uremia (blood urea above 250 mg/dL) the average HIF 1 mRNA levels were reduced by 
about 50 % compared to controls.  
The HIF 1 decline (figure 16) appeared particularly in animals with severe uremia and was not 
significantly different between controls and mildly uremic mice (n = 10, p = 0.73). The difference 
between controls and severely uremic mice, however, was highly significant (p = 0.008). In addition, 
the linear regression analysis of the correlation between HIF 1 expression and serum urea levels gave 
highly significant results (figure 17, p = 0.0021, n = 29, r = -0.55). A similar correlation was detected 
between HIF 1 expression and the vessel density in the cremaster muscle (figure 18, p = 0.0037, n = 
29, r = 0.52), as determined in a related study (Prommer, 2018). HIF 1 mRNA levels were, however, 
not significantly linked to the avΔO2 in the same muscle (figure 19, p = 0.0951, r = 0.53).  
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Figure 16: HIF 1 relative gene expression in the myocardium according to severity of serum uremia. 
HIF 1 gene expression was measured in controls (n = 13), mildly uremic mice  
(n = 10), and severely uremic mice (n = 6). There is a highly significant decrease of HIF 1 
expression in severely uremic animals when compared to controls (p = 0.008).  
 
Figure 17: Linear correlation analysis of HIF 1 gene expression in the myocardium and serum urea 
levels. The decline of HIF 1 expression correlated significantly with increasing serum urea 
levels (p = 0.0021, n = 29, r = -0.55). Designations of the diagram as described in figure 4. 
 
 






























Figure 18: Linear correlation analysis of HIF 1 gene expression in the myocardium and 
microvascular density in the cremaster muscle. HIF 1 expression also correlated 
significantly with microvascular density in the cremaster muscle (p = 0.0037, r = 0.52, n = 
29). Designations of the diagram as described in figure 4. 
 
Figure 19 Linear correlation analysis of HIF 1 gene expression in the myocardium and arterial-
venous difference in oxygen saturation. HIF 1 mRNA expression in the myocardium did 
not significantly correlate to the avΔO2 measured in cremaster muscle tissue (p = 0.0951, n 
= 11, r = 0.53). Designations of the diagram as described in figure 4. 
 




























































3.7.2 Myocardial VEGF Expression is not Significantly Affected by Uremia 
VEGF is thought to be one of the most important regulators of vessel growth and integrity. VEGF is also 
known as a potential target of HIF gene transcription activation.  
Compared to control animals (n = 13), VEGF expression in the heart of mildly uremic animals (n = 10) 
was not significantly different (figure 20, p = 0.069), and there was no significant difference in 
expression levels between mildly and severely uremic animals (n = 6, p > 0.999). Also, the comparison 
of controls (n = 13) with severely uremic animals (n = 6) gave no significant result (p = 0.33). In the 
linear regression analysis (figure 21), a weak correlation between VEGF expression and serum urea 
levels was detected which was, however, just under significance level (p = 0.059, r = -0.36, n = 29). 
Consistent with this finding, VEGF mRNA expression showed no significant correlation with microvessel 
density in the cremaster muscle (figure 22, p = 0.052, r = 0.37, n = 29).  
 
Figure 20: VEGF relative gene expression in the myocardium as a function of severity of serum 
uremia. VEGF gene expression was measured in controls (n = 13), mildly uremic mice (n = 
10), and severely uremic mice (n = 6). No significant correlation of VEGF expression and 
degree of uremia was detected.  
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Figure 21: Linear correlation analysis of VEGF gene expression in the myocardium and serum urea 
levels. Designations of the diagram as described in figure 4. No correlation between VEGF 
expression and serum urea levels were established (p = 0.059, r = -0.36, n = 29).  
Figure 22: Linear correlation analysis of VEGF gene expression in the myocardium and microvascular 
density in the cremaster muscle. Likewise, no correlation between VEGF expression in the 
myocardium and microvascular density in the cremaster muscle was detected (p = 0.052, r 
= 0.37, n = 29). Designations of the diagram as described in figure 4. 
 
 




























































3.7.3 VEGFR-2 Shows Decreased Myocardial mRNA Expression in Uremia 
VEGFR-2 is the main receptor thought to communicate vascular growth signals transmitted by VEGF. 
VEGFR-2 mRNA expression gradually deceased as urea levels rose in the respective animals.  
Again, the difference in mRNA expression between controls (n = 13) and mildly uremic animals (n = 10) 
was not significant (figure 23, p = 0.10), neither was the difference between mildly and severely uremic 
animals (n = 6, p = 0.81). There was, however, a striking difference if severely uremic animals were 
compared to controls (p = 0.009). Accordingly, linear regression analysis of the association of VEGFR-2 
expression with serum urea levels (figure 24) showed a highly significant trend (p = 0.016, r = -0.44, n 
= 29). Similarly, VEGFR-2 expression declined if cremaster muscle vessels had been rarefacted (figure 
25, p = 0.0065, r = 0.49, n = 29). 
 
Figure 23: VEGFR-2 relative gene expression in the myocardium according to severity of serum 
uremia. While there was neither a significant difference of VEGFR-2 expression between 
mildly uremic mice and controls (p = 0.10) nor between mildly uremic mice and severely 
uremic mice (p = 0.81), a highly significant difference can be shown between severely 
uremic animals and controls (p = 0.009).  
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Figure 24: Linear correlation analysis of VEGFR-2 gene expression in the myocardium and serum urea 
levels. VEGFR-2 gene expression was significantly correlated to serum urea levels (p = 0.016, 
r = -0.44, n = 29). Designations of the diagram as described in figure 4.  
Figure 25: Linear correlation analysis of VEGFR-2 gene expression in the myocardium and 
microvascular density in the cremaster muscle. Designations of the diagram as described 
in figure 4. VEGFR-2 expression in the heart correlated significantly with cremaster muscle 
vessel density (p = 0.0065, r = 0.49, n = 29).  
 
3.7.4 Ang-2 but not Ang-1 Transcription is Decreased in the Myocardium of Uremic Mice 
The mRNA levels of Ang-1, a main pro-angiogenic compound of the endothelium, were not affected 

































































were compared to controls (n = 13) (figure 26, p = 0.99). The linear regression showed neither a 
significant correlation between Ang-1 expression and serum urea levels (figure 27, p = 0.51, r = -0.13, 
n = 29) nor with microvessel rarefaction in the cremaster muscle (figure 28, p = 0.088, n = 29, r = 0.32). 
In contrast, Ang-2 expression showed a sensitive reaction to increasing urea levels (figure 29). 
Compared to controls (n = 13), there was already a significant decrease (p = 0.019) in mildly uremic 
mice (n = 10) and this trend was not further increased in severely uremic animals (n = 6). Linear 
regression showed a significant correlation between Ang-2 expression decline, serum urea levels 
(figure 30, p = 0.0094, r = -0.47, n = 29) and microvessel rarefaction in the cremaster muscle (figure 31, 
p = 0.0075, r = 0.49, n = 29). 
This finding showed that with increasing serum urea concentrations, there was a shift in the Ang-
1/Ang-2 ratio (figure 32). The Ang-1/Ang-2 ratio, a plain numerical value, rose from approximately 2 in 
controls to approximately 5 in severely uremic animals. The linear regression analysis showed a highly 
significant correlation with serum urea levels (p = 0.0064, r = 0.49, n = 29). The same pattern was found, 
if Ang-1 and Ang-2 were tested against a correlation with microvessel density (data not shown).  
 
Figure 26: Ang-1 relative gene expression in the myocardium according to severity of serum uremia. 
Ang-1, a proangiogenic gene regularly expressed in endothelium, showed no significant 
correlation in myocardial expression levels with the serum urea levels. 
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Figure 27: Linear correlation analysis of Ang-1 gene expression in the myocardium and serum urea 
levels. Ang-1 expression in the myocardium shows a large variation and no significant 
correlation with serum urea levels (p = 0.51, r = -0.13, n = 29). Designations of the diagram 
as described in figure 4. 
 
Figure 28: Linear correlation analysis of Ang-1 gene expression in the myocardium and 
microvascular density in the cremaster muscle. Likewise, no correlation between Ang-1 
expression in the myocardium and microvascular density in the cremaster muscle was 
established (p = 0.088, r = 0.32, n = 29). Designations of the diagram as described in figure 4. 



























































Figure 29: Ang-2 relative gene expression in the myocardium as a function of severity of serum urea. 
There was a significant difference of Ang-2 expression between mildly uremic mice and 
controls (p = 0.019), with no further trend between mildly uremic mice and severely uremic 
mice (p > 0.999). The difference between controls and severely uremic animals was 
significant at p = 0.048. 
Figure 30: Linear correlation analysis of Ang-2 gene expression in the myocardium and serum urea 
levels. Designations of the diagram as described in figure 4. Ang-2 gene expression was 
inversely correlated with serum urea levels (p = 0.0094, r = -0.47, n = 29). 































Figure 31: Linear correlation analysis of Ang-2 gene expression in the myocardium and 
microvascular density in the cremaster muscle. Ang-2 expression in the cardiac muscle is 
significantly correlated with the cremaster muscle vessel density (p = 0.0075, r = 0.49, n = 
29). Designations of the diagram as described in figure 4.  
Figure 32: Linear correlation analysis of Ang-1/Ang-2 gene expression ratio in the myocardium and 
serum urea levels. The ratio of proangiogenic Ang-1 and antiangiogenic Ang-2 gene 
expression is thought to create a net proangiogenic or antiangiogenic environment, 
respectively. Therefore, plotting the Ang-1/Ang-2 gene expression ratio against the serum 
urea levels reveals a highly significant trend towards a proangiogenic environment in the 
















































3.7.5 Common Ang Receptor Tie-2 Transcription is Downregulated in Severe Uremia 
Both Ang-1 and Ang-2 proteins are believed to bind to the Tie-2 receptor. Tie-2 mRNA expression levels 
in the myocardium showed a significant decrease in severely uremic animals (n = 6) when compared 
to controls (n = 13) (figure 33, p = 0.024). The differences were not yet significant between controls 
and mildly uremic mice (n = 10). Consistent with these results, the linear regression analysis (figure 34) 
showed that Tie-2 expression was negatively correlated with serum urea levels (p < 0.0001, r = -0.68, 
n = 29) and positively correlated with microvessel density in skeletal muscle (figure 35, p = 0.0017, r = 
0.44, n = 29). 
 
Figure 33: Tie-2 relative gene expression in the myocardium as a function of severity of serum urea. 
Tie-2 expression was neither significantly different between mildly uremic mice and 
controls (p = 0.24) nor between mildly uremic mice and severely uremic mice (p = 0.81). 
There was, however, a significant difference between severely uremic animals and controls 
(p = 0.024), suggesting that Tie-2 expression in the heart declined particularly at higher 








Figure 34: Linear correlation analysis of Tie-2 gene expression in the myocardium and serum urea 
levels. The myocardial gene expression of Tie-2, which is thought to act as a receptor for 
Ang-1 as well as for Ang-2, was inversely correlated with serum urea levels (p < 0.0001,  
r = -0.68, n = 29). Designations of the diagram as described in figure 4 
Figure 35: Linear correlation analysis of Tie-2 gene expression in the myocardium and microvascular 
density in the cremaster muscle. Although cardiac Tie-2 expression showed considerable 
variation, it was significantly correlated to cremaster muscle vessel density (p = 0.0017, r = 
































































3.7.6 Orphan Receptor Tie-1 mRNA Levels are Negatively Affected by Uremia 
Tie-1 mRNA levels in the heart were significantly lower in severely uremic animals (n = 6) as compared 
to controls (n = 13) (figure 36, p = 0.036). The drop of gene expression between controls and mildly 
uremic animals (n = 10) was, however, not significant (p > 0.999), possibly indicating that a stronger 
metabolic strain is required to produce this effect. Again, there was a consistent negative correlation 
of Tie-1 mRNA levels and increasing serum urea (figure 37, p = 0.0016, r = -0.56, n = 29) and a positive 
correlation of Tie-1 mRNA levels and the density of the microvasculature in cremaster muscle (figure 
38, p = 0.019, r = 0.43, n = 29).  
Figure 36: Tie-1 relative gene expression in the myocardium according to serum urea levels. Tie-1 is 
an orphan receptor that is thought to interact with the Tie-2 receptor. In line with the Tie-
2 expression decline in uremic animals, Tie-1 expression is significantly lower in severely 










Figure 37:  Linear correlation analysis of Tie-1 gene expression in the myocardium and serum urea 
levels. Expression of orphan receptor Tie-1 in the cardiac muscle was negatively correlated 
with serum urea levels (p = 0.0016, r = -0.56, n = 29). Designations of the diagram as 
described in figure 4. 
 
Figure 38:  Linear correlation analysis of Tie-1 gene expression in the myocardium and microvascular 
density in the cremaster muscle. Similar to the Tie-2 receptor which is thought to interact 
with the Tie-1 receptor, Tie-1 expression was significantly correlated with microvascular 
density of the cremaster muscle (p = 0.019, r = 0.43, n = 29). Designations of the diagram 
































3.7.7 Matrix Metalloprotease MMP-9 but not MMP-2 Transcription is Reduced in 
Myocardium of Uremic Mice 
Vessel regression as well as vessel growth requires the activity of extracellular matrix (ECM) modifying 
enzymes. There was a significant difference between cardiac MMP-9 expression in controls (n = 13) 
and severely uremic mice (n = 6, p = 0.024, figure 42). The difference of expression levels was much 
less pronounced between controls and mildly uremic animals (n = 10) (p = 0.26). Furthermore, the 
linear regression analysis showed a significant negative correlation of mRNA expression to increasing 
serum urea levels (figure 43, p = 0.038, r = -0.39, n = 29) and a positive correlation particularly to 
microvessel density (figure 44, p = 0.0008, r = 0.59, n = 29). In contrast, expression levels of MMP-2 
seemed largely unaffected by serum urea levels (figure 39, p > 0.999). Accordingly, linear regression 
showed no correlation between MMP-2 expression and serum urea (figure 40, p = 0.67, r = 0.08, n = 
29) or vessel rarefaction (figure 41, p = 0.77, r = -0.06, n = 29). 
 
 
Figure 39: MMP-2 relative gene expression in the myocardium as a function of levels of serum urea. 
MMP-2, a matrix metalloprotease with an assumed role in vessel remodeling and 
rarefaction, shows no significant correlation in myocardial expression levels with different 




Figure 40: Linear correlation analysis of MMP-2 gene expression in the myocardium and serum urea 
levels. Although matrix metalloproteases are thought to play a role in vascular remodeling, 
no correlation of MMP-2 expression in the myocardium and serum urea levels was found 
(p = 0.67, r = 0.08, n = 29). Designations of the diagram as described in figure 4. 
 
 
Figure 41: Linear correlation analysis of MMP-2 gene expression in the myocardium and 
microvascular density in the cremaster muscle. No correlation between MMP-2 expression 
in the myocardium and microvascular density in the cremaster muscle was detected (p = 
0.77, r = -0.06, n = 29). Designations of the diagram as described in figure 4. 
 



























































Figure 42: MMP-9 relative gene expression in the myocardium as a function of severity of serum 
urea. MMP-9, a matrix metalloprotease closely related to but differentially regulated from 
MMP-2, showed a significant difference in myocardial expression levels (p = 0.024) between 
severely uremic animals (n = 6) and controls (n = 13).  
 
Figure 43: Linear correlation analysis of MMP-9 gene expression in the myocardium and serum urea 
levels. MMP-9 matrix metalloprotease gene expression was significantly associated with 
serum urea levels (p = 0.038, r = -0.39, n = 29). Designations of the diagram as described in 
figure 4. 































Figure 44: Linear correlation analysis of MMP-9 gene expression in the myocardium and 
microvascular density in the cremaster muscle. MMP-9 expression was significantly 
increased with increasing microvascular density of the cremaster muscle (p = 0.0008, r = 
0.59, n = 29). Designations of the diagram as described in figure 4. 
 
3.7.8 Summary of Myocardial Gene Expression Results in Uremia 
In summary, experimental uremia in mice was associated with an expression decline in many of the 
investigated genes regulating angiogenesis, while others remained not significantly affected. Below 
(table 3), a comparison of the results provides an overview of the detailed analyses of the previous 
sections. As certain genes or gene products are linked in signaling pathways or effector cascades, the 


































Table 3: Summary of the gene expression levels in cardiac muscle of uremic and control mice. Nine 
genes with a proven involvement in vessel angiogenesis, maintenance and disruption were 
tested in uremic animals vs. controls. Column 1 gives the gene name. Column 2 shows the 
significant expression change tendencies which were experimentally observed in uremic 
animals compared to controls. Column 3 shows an expected tendency in expression change 
of these genes in a functioning network if hypoxia is assumed (see 1.2.1), while column 4 
depicts whether the actual findings are concordant or discordant with these expectations 
from such a simplistic model. Column 5 shows an assumed correlation of genes or gene 
products, either as effector genes (green: HIF 1α and its assumed effector genes, Dengler 
et al., 2014), or as members of the same signaling pathway (taken from the KEGG pathway 
database, http://www.genome.jp/kegg/pathway.html; yellow: VEGF signaling pathway; 
pink: Ang/Tie-2 signaling; purple: Tie-2/Tie-1 regulation, Savant et al., 2015; because of 
their multiple functions, MMPs were not allocated to distinct pathways). Column 6 
indicates whether the actual experimentally detected decline in the expression of individual 
genes is associated with the disruption of an entire signaling pathway or the reduction of 
the expression of effector genes. N.s.: not significant;  downregulated gene expression,  
 upregulated gene expression. 
 

















HIF 1α  p=0.008  no     yes 
VEGF n.s. p=0.334  no     — 
VEGFR-2  p=0.009  no     yes 
Ang-1 n.s. p=0.993  no     — 
Ang-2  p=0.048  yes     — 
Tie-2  p=0.024  no     yes 
Tie-1  p=0.036 ? ?     yes 
MMP-2 n.s. p>0.999 ? ?     — 






4.1 Uremia Models 
Both methods employed, 5/6 NX and adenine feeding, reliably led to uremia in BALB/c mice. Selection 
of the appropriate mouse strain is crucial, as not every strain is sensitive to such treatments. It has 
been reported that C57BL6 mice do not develop CKD upon 5/6 NX (Leelahavanichkul et al., 2010). 
There was a significant difference in the severity of uremia which was achievable in BALB/c mice with 
the two methods. While 5/6 NX led to moderate uremia only, adenine feeding partly led to very severe 
uremic conditions. There was also a striking difference in the pace of uremia development between 
the two experimental models. 5/6 NX mice developed uremia slowly over a period of 4 months (Fogo, 
2003; Ferrari et al., 2014), while adenine-fed mice were severely uremic after a 4 week feeding period. 
Both approaches showed a considerable heterogeneity within the respective groups in terms of 
uremia, although the experimental regime was kept uniform during the study period, suggesting that 
individual differences in the background, behavior or—depending on the methodology—either food 
intake or surgery, may play a role in uremia development. Particularly in the 5/6 NX microsurgery, 
subtle differences in the amount and/or region of tissue removal may account for differences in the 
experimental outcome, as the remaining kidney tissue tends to develop compensatory hypertrophy. 
Development of CKD in mice was monitored by determining the serum urea level. The increase in 
serum creatinine levels, which is regularly used as a marker in CKD patients, is less pronounced in mice 
and may be delayed, particularly in the adenine model (Tamura et al., 2009; Oyama et al., 2010). 
Although differences could be detected in creatinine levels between uremic groups and controls, none 
of these were significant, probably due to the considerable variation in the measured values. 
Experimental models affect body weight quite differently (Mori-Kawabe et al., 2015); as expected, 
adenine-fed mice lost considerable amounts of body weight, while 5/6 NX mice in general showed a 
slight body weight gain over time.  
In conclusion, the above data suggest that 5/6 NX is a good model for a slow uremia development, 
which is seen in many patients who may remain asymptomatic for a long time. In contrast, the adenine 
model is much more aggressive, as it leads to progressive deterioration of renal function in a short 
time. There was, however, a strong negative correlation between serum urea levels and microvessel 
density in the cremaster muscle, irrespective of the uremia-inducing method (Prommer, 2018), 
suggesting that both experimental approaches resulted in a similar dose-dependent effect on 
microvessel rarefaction. To rule out the possibility that the observed functional changes were due to 
emaciation rather than to uremia, a multivariate regression analysis was performed in a related study 
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(Prommer, 2018), clearly attributing the results of the cohort to the severity of uremia as indicated by 
serum urea levels. 
Inherent to the intravital microscopy technology on cremaster muscle used to study the structural and 
functional alterations of the microvasculature in uremia is the restriction to male experimental 
animals. This inevitable preference of one sex may be one limitation of the significance of this study. 
These basic research findings will have to be tested for their clinical relevance in further gender-
balanced studies (Clayton & Collins, 2014). Indeed, there is a slight preponderance of kidney failure as 
well as in kidney transplant indication in men (Saran et al., 2016). No reports exist up to now, however, 
which would suggest a significant sex difference in the cardiac morbidity or mortality from CKD in 
juvenile patients.  
 
4.2 Microvascular Rarefaction in Skeletal and Cardiac Muscles 
The microvessel density in the skeletal muscle of severely uremic mice was reduced by approximately 
50 % (Prommer, 2018). The degree of rarefaction was strongly correlated with serum urea levels. 
Correspondingly, microvessel density in the cardiac muscle of identical animals was reduced on the 
same scale, suggesting a systemic effect of uremia (figure 13). In another study, data from ex vivo 
biopsies from the omentum of children with stage 5 CKD showed a reduction of microvessel density 
from 36 to 51 % (Burkhardt et al., 2016) which is within the same range as the findings of this work. 
Vascular rarefaction in cardiac muscle was also detected in a post mortem study performed on samples 
from hemodialysis patients (Amann et al., 1998). The fact that microvascular rarefaction is seen in 
various organs, and even muscle types, suggests that the accumulation of harmful substances in the 
blood may have a detrimental effect on the entire organism (Vanholder et al., 2008). Systemic 
microangiopathy, induced by chronic uremia, may occur early in the disease process and could be the 
sought-after link between CKD and damage to the cardiovascular system (Shroff et al., 2008), 
crystallizing in the profound increase in cardiac mortality in this patient group.  
The molecular mechanisms of microvascular rarefaction remain unclear. Apoptosis is an evident 
mechanism for the depletion of vessel density. Evidence for apoptosis, however, may be time-
dependent and the process may well escape detection if vessels have already vanished at the time of 
investigation. Pruning of vessel branches may also involve endothelial cells re-assembling into other 
vessels (Franco et al., 2015) or de-differentiation (Feinberg & Noden, 1991) in an endothelial to 
mesenchymal transition. This process in turn might contribute to the exacerbation of the existing 
disease (Zeisberg et al., 2007), as the arising fibroblasts will further constrain the oxygen supply 
(Charytan et al., 2014). Irrespective of the underlying mechanism, the initial damage to the 
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microvessels could be the starting point of a downward spiral for the entire organism. The 
microvasculature is a metabolic tissue in its own right, accumulating to more than 1 kg of human body 
weight (Clough, 2015). An initial restriction in blood flow could also have a detrimental effect on 
nutrient and oxygen supply of the vessels itself. This supposed effect would be more pronounced in 
small vessels because they have an adverse surface to volume ratio. The resulting rarefaction and 
subsequent oxygen deficiency would first become clinically apparent in the most vulnerable organ 
systems.  
 
4.3 Alterations of Gene Expression in the Myocardium Correlate with Serum 
Urea Levels and Vessel Density in the Skeletal Muscle 
Gene expression in the heart of uremic mice was significantly diminished for several angiogenic factors, 
while others remained unaffected. Transcription factors, pro- and anti-angiogenic cytokines and their 
respective receptors, however, make up such a delicate interdependent system that signaling might 
be impaired even if only individual components of a signaling cascade are downregulated on the mRNA 
level.  
4.3.1 Adverse HIF 1 Response 
Analysis of microvascular density showed a significant reduction in uremic groups (Prommer, 2018). 
This vascular rarefaction is associated with a reduced avΔO2 and suggests that hypoxia is widespread 
in tissue with rarefacted microvasculature. Indeed, elevated HIF 1 levels have been reported in kidney 
tissue of patients with CKD (Nangaku, 2006; Rudnicki et al., 2009). In contrast, in this work a significant 
decrease of HIF 1 mRNA levels in the myocardium of mice with vascular rarefaction in the cremaster 
skeletal muscle was shown, suggesting that a systemic effect impairs both cardiac and skeletal muscle. 
These findings are consistent with a study in rats with advanced renal failure, where reduced HIF 1 
levels were detected in response to systemic hypoxia (Flisinski et al., 2012). An activation of HIF 1—
as a fundamental molecular switch to cope with oxygen deficiency—would be expected to protect 
body tissue from hypoxia and thus from potential loss. There are various possibilities to explain that 
this is not necessarily the case: (1) The HIF 1 downregulation could be tissue-specific. At rest, the 
kidney has the highest oxygen consumption proportional to its weight and therefore receives the 
largest fraction of the cardiac output. Even under physiological conditions, the renal medulla provides 
a hypoxic environment due to the immense transporter activity and the resulting highly specific 
vascular formation (Heyman et al., 1997), making HIF 1 upregulation in the kidney likely, while it 
could be downregulated in other organs. (2) Expression profiling is a snapshot of the current expression 
level in a certain disease state. The disease could either be not far advanced yet, so HIF 1 is not yet 
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activated, or could have reached an advanced stage so that the tissue is already exhausted and the 
general metabolism is impaired (Chade, 2011). (3) Hypoxia is a known stimulus for inflammation (Kong, 
2004). Fibroblasts in hypoxia can switch to a fibrogenic phenotype, inducing TIMPs which results in an 
accumulation of ECM which further hinders blood flow and oxygen diffusion (Fine & Norman, 2008; 
Haase, 2009). It can be speculated that the depletion of HIF 1 (and possibly some of its target genes) 
provide a protective mechanism to avoid this vicious circle, even at the cost of hypoxia (Mayer, 2011). 
Indeed, chronic hypoxia can lead to HIF 1 suppression via several routes (Fu et al., 2016). In this 
context, it is noteworthy that von Hippel-Lindau knockout mice, which are incapable of degrading HIF 
1, show increased interstitial fibrosis (Kimura et al., 2008). Moreover, long-term upregulation of HIF 
1 has been associated with the progression of chronic renal injury (Zhu et al., 2011).  
In conclusion, in tissue showing severe vessel rarefaction and thus experiencing chronic hypoxia, a 
strong pro-angiogenic signaling would be expected. Data from this study suggest, however, that in 
uremic animals, the core response to hypoxia is heavily disturbed on a systemic level. Similar data were 
derived from a 5/6 NX rat model (Jacobi et al., 2006). Thus, the failure of an adequate pro-angiogenic 
response to hypoxia may be a critical step towards a downward spiral in chronic kidney disease.  
4.3.2 Disruption of VEGF Signaling 
In this study, VEGF mRNA levels in the myocardium were not significantly affected by uremia/ 
rarefaction (figure 20). This is contradictory to the finding of some authors (Rudnicki et al., 2009) that 
VEGF is upregulated in hypoxia. However, VEGF protein was significantly decreased in another study 
(Iliescu et al., 2010), possibly reflecting post-transcriptional mechanisms or an increased depletion of 
the protein. It has, however, been shown by others (Kang et al., 2001), that prolonged hypoxia may 
lead to a drop in VEGF expression. In a rat model of CKD, kidney proximal tubular cells showed an initial 
increase in VEGF expression followed by a depletion of both, VEGF and VEGFR expression levels with 
subsequent endothelial cell apoptosis and vessel regression (Ohashi et al., 2002). Interestingly, in the 
present work, the VEGFR-2 was downregulated in rarefacted heart tissue (figure 23) which is consistent 
with studies in artery endothelial cell lines (Olszewska-Pazdra et al., 2009). This data corroborates that 
chronic hypoxia can lead to a downregulation of VEGF signaling although VEGF expression remains 
stable. It has been shown previously, that VEGF signaling may also be disturbed at the 
posttranscriptional level in the rarefacted mesentery of hypertensive rats (Tran et al., 2011). A recent 
study (Shi et al., 2013) found that VEGF signaling may be controlled by a microRNA targeting 1 integrin 
which is required for VEGFR-2 phosphorylation (Chen et al., 2010). 
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4.3.3 Disruption of Ang/Tie-2 Signaling 
While Ang-1 levels remained insensitive to blood urea levels (figure 27) and microvascular rarefaction 
(figure 28), Ang-2 levels decreased markably already at mild serum urea levels (figure 29). Ang-1 is 
usually considered to be pro-angiogenic and Ang-2 is considered to be destabilizing and anti-
angiogenic. The Ang-1/Ang-2 ratio is thought to determine a pro-angiogenic or anti-angiogenic 
environment (Eklund & Olsen, 2006). This study shows that the Ang-1/Ang-2 ratio increased from a 
numerical value of approximately 2 in controls to approximately 5 in uremic animals, creating a more 
pro-angiogenic environment (figure 32), suggesting an attempt of the cardiac tissue to counter a 
possible tissue hypoxia. This finding is consistent with results of a recent study (Burkhardt et al., 2016) 
which showed in quantitative immuno-histochemical stainings of mesentery biopsies from children 
suffering from CKD that Ang-1 levels were not significantly altered compared to healthy controls, but 
Ang-2 levels were significantly decreased, likewise resulting in a profound increase in Ang-1/Ang-2 
ratio. The expression of the Tie-2 receptor which binds both angiopoietins, however, decreases with 
increasing blood urea levels (figure 33). This effect was significant only if severely uremic mice were 
compared to controls, suggesting that higher urea levels are required to generate this effect. 
Transferring these findings to CKD patients would imply that Ang/Tie-2 signaling is disturbed only at 
the advanced disease stage. Therefore, Tie-2 downregulation may lead to an impaired Ang-1 signaling 
although Ang-1 levels remain relatively stable.  
Tie-1, which is thought to be a co-regulator of Tie-2 function (Savant et al., 2015), is also downregulated 
in rarefacted tissues (figure 38). Although no ligand has been confirmed for the Tie-1 receptor to date, 
the molecule seems to be involved in the regulation of vessel stability and remodeling. This notion is 
supported by the fact that Tie-1 mRNA levels in cardiac muscle were significantly lower in severely 
uremic animals as compared to controls (figure 36).  
4.3.4 Regulation of Matrix Metalloproteases 
Vascular network formation, remodeling, or regression requires alterations in the extracellular matrix 
(ECM). The ECM is controlled largely by a system of enzymes termed matrix metalloproteases (MMPs) 
degrading the ECM, and their negative regulators, the tissue inhibitors of matrix metalloproteases 
(TIMPs). The role of MMPs is ambiguous, as they may play an active role in angiogenesis as well as in 
vessel regression and can thus have both pro- and anti-angiogenic effects. MMP-2 and its paralog 
MMP-9 are capable to break down collagen IV of the basal membrane. Despite their similarity, MMP-
2 and MMP-9 are thought to be differentially regulated (Galis et al., 2002; Xie et al., 2004), implying 
distinct biological functions. On the one hand, MMPs can promote angiogenesis by enabling pericytes 
to detach from vessels, by releasing cell adhesions of endothelial cells, by releasing pro-angiogenic 
growth factors from the ECM, or by exposing cryptic integrin binding sites in the ECM. On the other 
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hand, MMPs may also cause angiogenic arrest by producing anti-angiogenic effectors from degraded 
ECM or by converting plasminogen to angiostatin (Raffetto & Khalil, 2008). In addition, MMPs can 
modulate cell receptor signaling by cleaving off their ligand-binding domains (Tran et al., 2011).  
This work shows that MMP-9 but not MMP-2 decreased in heart tissue of uremic mice. A decrease for 
both of these enzymes was previously reported in a porcine model of renovascular disease (Chade et 
al., 2003). In contrast, in spontaneously hypertensive rats with microvascular rarefaction, increased 
activity of some MMPs, including MMP-9, was found in the mesentery (Tran et al., 2011). In line with 
data from this study, the authors found no expression change for MMP-2. They showed that along with 
increased MMP activity, the extracellular domain of the VEGF receptor VEGFR-2 was depleted, possibly 
indicating that circulating MMPs are responsible for this proteolytic activity. Inhibition of MMPs could 
also attenuate microvascular rarefaction, suggesting that MMP-mediated decrease of VEGF signaling 
triggers rarefaction. However, the authors concede, that increased MMP activity was found mainly 
along venules, while the depletion of the extracellular VEGFR-2 domain was detected along arterioles 
and capillaries. In addition, the employed MMP inhibitor, doxycycline, is known to have also strong 
anti-inflammatory effects, even at low doses which do not yet have antibiotic properties (Krakauer & 
Buckley, 2002). In 2008, this effect even led to the FDA and EMA approval of low dose doxycycline as 
an anti-inflammatory drug in some chronic inflammatory conditions. It can therefore not be ruled out 
that the attenuation of rarefaction observed is due to a reduced inflammatory response induced by 
the MMP inhibitor rather than to the reduced MMP activity itself. It should also be mentioned that 
MMPs are usually produced as zymogens in a quiescent form which need other MMPs or triggers for 
activation. Activators of MMPs include reactive oxygen species (ROS) and NO. Therefore, mRNA levels, 
protein levels, and enzymatic activity of MMPs may diverge considerably and should be analyzed 
separately in dedicated experimental settings.  
4.3.5 Myocardial Gene Expression Changes Imply a Systemic Impact of Uremia 
Several studies on the skeletal muscle suggest that uremia leads to rarefaction of the microvasculature 
and subsequent tissue hypoxia in the affected tissues (Flisinski et al., 2014; Prommer, 2018). This study 
demonstrates that myocardial microvascular changes in uremic animals parallel microvascular 
rarefaction in the skeletal muscle. Cardiac vessel regression is strongly linked to serum urea levels, 
implying a systemic impact of uremia on the microvasculature (figure 13). A significant reduction of 
vessel density is observed already in mildly uremic animals, suggesting that already mild renal 
impairment may trigger this process. 
In healthy tissue, hypoxia induces HIF 1 to produce an extensive cellular response involving many HIF 
1 target genes. In chronic uremia, however, this response is reversed. It is not clear, whether the HIF 
1 downregulation observed is the cause or the effect of this reversal. Pro-angiogenic signaling is 
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impaired, because expression of both transferring receptors, VEGFR-2 and Tie2, are decreased. The 
shift of the Ang-1/Ang-2 ratio towards a more pro-angiogenic environment can be construed as a futile 
attempt of counterregulation in hypoxic tissue. This regulatory attempt will, however, not be 
successfully transferred due to a downstream disruption of Tie-2 signaling. In conclusion, these data 
suggest a systemic effect, leading to an inadequate response to prolonged hypoxia and a profound 
dysregulation of vessel maintenance which may eventually result in microvascular rarefaction.  
 
4.4 Microvascular Rarefaction Precedes Macrovascular Alterations 
The data presented above showed a profound structural microvascular depletion in the skeletal 
(Prommer, 2018) as well as in the cardiac muscle, suggesting that CKD affects the microvasculature on 
a systemic level. This degradation leads to a functional impairment of the microvasculature, hampering 
oxygen and nutritional supply to the tissue. Despite these striking effects in the microvasculature, a 
comparative staining of aortal cross sections did not show any atherosclerotic changes in severely 
uremic animals (figure 15 A, B). In fact, no difference was detected between aortas from severely 
uremic animals and those from negative controls. Although it is known that mice hardly develop 
atherosclerosis, the positive controls, which were nephrectomized and treated with 2 % phosphate 
and 1 µg/kg calcitriol in a separate experiment, prove that such changes may develop under harsh 
treatments (figure 15 C). If atherosclerotic changes in the mouse model require very high serum urea 
and/or phosphate levels to occur, these will be indiscernible in the 5/6 NX model, as it only leads to 
moderate uremia. In the adenine model, the four-week time period allowed for severe uremia to 
develop may be too short a time to reveal such macrovascular changes. This result parallels findings in 
CKD patients. Children with CKD showed a marked microvascular rarefaction in the omentum 
(Burkhardt et al., 2016). However, signs of atherosclerosis are absent in children with CKD, while 
elderly CKD patients with accumulated cardiac risk factors generally do show atherosclerosis (Shroff et 
al., 2008). The presence of early microvascular changes in the myocardium suggests that these may 
play a crucial role in cardiac events in juvenile CKD patients. Capillary rarefaction in the myocardium 
will lead to a decreased capillary to myocyte ratio, a so-called capillary to myocyte mismatch (Amann 
et al., 2000). The resulting deficit in oxygen and nutrient supply could trigger hypoxia and inflammation 
which ultimately results in fibrotic remodeling of the myocardium. Moreover, cardiac fibrosis may have 
several secondary deleterious effects such as myocardial stunning, i.e. the transient inability of a 
myocardial region to contract. Myocardial stunning is shown to be induced by long-term hemodialysis 
and is associated with increased cardiac mortality in pediatric CKD patients (Hothi et al., 2009). These 
data suggest that the microangiopathy in CKD patients might be an early sign of an ongoing disease 
process.   
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4.5 Impairment of Oxygen Delivery in Uremia 
4.5.1 Oxygen Uptake Impairment  
Oxygen diffusion flow in a given environment can be approximated using  
 
where  
J = diffusion flow 
D = diffusion coefficient 
A = diffusion surface 
dc = concentration difference 
dx = diffusion distance. 
A significantly reduced capability of oxygen uptake was shown for both 5/6 NX and adenine uremia 
models. It may be hypothesized that tissue which is hypoxic due to a rarefacted microvasculature 
displays a raised concentration difference dc compared to normoxic tissue. Oxygen from arterial blood 
supplying such a hypoxic region would then be extracted more vigorously, contributing to an increased 
avΔO2. The experimental finding in this study, however, was the opposite, as the avΔO2 of vessels 
above 16 µm in rarefacted muscle tissue was significantly diminished compared to controls. There are 
several explanations for this finding: (1) Rarefaction of capillaries leads to a reduction of diffusion 
surface A and an increase of the diffusion distance dx and thus, to a reduced oxygen unload. Moreover, 
the so-called phase separation effect, leading to an uneven cell and plasma distribution between larger 
and smaller vessels in their respective branching points, adds to the heterogeneity of rarefacted 
networks (Pries & Secomb, 2003) and thus to a lower oxygen delivery in microvascular beds. (2) The 
necessity of blood distribution throughout the tissue requires many junctions between the feeding 
arteriole and the draining venule, close and remote, resulting in short and long flow pathways (Pries 
et al., 2010). Wall shear stress is negatively correlated with the length of the respective pathway, i.e. 
shear stress is higher in short pathways. High shear stress induces vasodilatation, leading to a 
decreased flow resistance and subsequently to an increased blood flow in the short pathway. Flows in 
short low resistance pathways bypassing long pathways constitute functional shunts which further 
raise the diffusion distance dx and additionally reduce passage time required for reaching diffusion 
equilibrium (Pries et al., 2010). (3) To prevent functional shunting, metabolic information from the 
microvasculature must be transferred to the attached neighboring venules and arterioles. While 
information transfer in venules can be accomplished with the blood flow, information transfer in 
arterioles requires an upstream transfer which involves connexins to form gap junctions (Buschmann 
et al., 2010). A failure of this process could spark functional shunting and thus aggravate hypoxia. It is 
known that protracted hypoxia can lead to connexin dephosphorylation, resulting in a loss of function 
(Solan et al., 2007). Also, the restoration of blood flow in damaged microvasculature by angiogenesis 
Fick’s law:  J = – D A dc/dx 
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may lead to increased functional shunts (Chade, 2011). It has been shown previously that 
spontaneously hypertensive rats develop arteriovenous shunts that gradually substitute normal 
microvascular networks (Murfee & Schmid-Schönbein, 2008). (4) In addition, uremia-associated 
endothelial damage may lead to leaky microvasculature. Leaking compounds may not only result in 
the deterioration of surrounding parenchyma but also to a further reduction in transport of nutrients 
and oxygen to its respective destination area.  
4.5.2 Uremia Leads to Impaired Regulation of Vascular Tone 
Myogenic tone is a property of resistance vessels, small arteries and arterioles that can adapt their 
caliber depending on neural signals, metabolic signals, or shear stress. Upon experimentally induced 
complete vessel relaxation, the relative arterial diameter increase in mildly uremic mice was slightly 
impaired compared to controls while it was very limited in severely uremic mice. According to Hagen-
Poiseuille’s Law, this deprives the affected tissue of its ability to effectively regulate perfusion, as 
changes in the vessel radius enter into the formula with their fourth power. Since this effect is much 
more pronounced in severely uremic animals it can be assumed that circulatory dysregulation is a 
symptom of an advanced disease process.  
At least three different mechanisms may explain the reduced ability to increase vessel diameter: (1) It 
has been shown previously that in CKD the overall production of NO is reduced (Baylis, 2008). This 
would render the vessels incapable of fully dilating to their biological limit. A reduction in bioavailability 
of NO is believed to be a major contributor to altered vasoresponsiveness. The development and 
progression of vascular disease, including atherosclerosis, coronary heart disease and hypertension 
have been associated with both a reduced NO production and an increased generation of ROS in 
conjunction with compromised endogenous antioxidant defenses (Gao et al., 2009). The experimental 
use of sodium nitroprusside which acts as an NO donor and thus delivers an excess of NO, however, 
makes this explanation unlikely. (2) Pathological processes in the intima or media of the vessel wall 
could reduce the vessels’ compliance, limiting the maximum achievable vessel diameter. Indeed, it has 
been shown in CKD patients that calcification of the vessel intima and media leads to increased vessel 
stiffening and to a reduced compliance. Children with ESRD show an increased arterial stiffness which 
is comparable to elderly patients (Covic et al., 2006). Acetylcholine and sodium nitroprusside-mediated 
vasodilatation in adults between 20 and 45 years of age suffering from advanced CKD is decreased and 
is comparable to both elderly healthy controls and elderly patients suffering from CKD. This suggests a 
premature aging of the vasculature in CKD patients (Thang et al., 2012). (3) Finally, vessels in rarefacted 
uremic tissue could already be dilated in order to compensate for an impending hypoxia by increased 
blood flow so that no further dilation is possible. This adaptive response was already described in acute 
and chronic hypoxia (Marshall, 2015). 
62 
The impaired tone regulation limits the ability of perfusion regulation which ensures the appropriate 
blood supply of all body regions under physiological conditions. The decrease of vessel tone with 
increasing rarefaction supports both of the two latter explanations. However, as the goal of this study 
was to achieve the maximum vasodilatation, the experimental design to determine the vascular tone 
did not allow for discrimination of endothelium-dependent and endothelium-independent response.  
In another study, tension of mouse aortas was studied post mortem. First, vessel contraction was 
induced by phenylephrine. Subsequently, acetylcholine or sodium nitroprusside was added to measure 
endothelium-dependent or endothelium-independent relaxation, respectively (Mori-Kawabe et al., 
2015). The authors found a decreased acetylcholine effect in adenine-fed mice, indicating an 
endothelial dysfunction, while no difference in endothelium-independent relaxation could be shown. 
Further experiments have to show which mechanism is the leading cause of the constraint observed. 
 
4.6 The Role of Prolonged Inflammation 
Both, uremia and hypoxia enhance the expression of a multitude of pro-inflammatory mediators (Fine 
& Norman, 2008; Rockey et al., 2015). Chronic inflammation may have a deleterious effect on organ 
function by increased fibrosis, increased generation of ROS, or increased oxygen consumption which 
further promotes hypoxia. Systemic inflammatory processes have the potential to initiate a vicious 
circle in which the primary defect further affects the system leading to further deterioration: Renal 
failure causes retention of toxic compounds in the blood which lead to endothelial damage and 
continuous systemic inflammation. In addition, inflammation of the cardiac muscle may lead to cardiac 
failure which in turn causes hypoperfusion and ischemia of the kidneys resulting in a reduced GFR, 
which is again causative for uremia (Mutsaers et al., 2015). 
Therefore, the leukocyte rolling velocity in postcapillary venules was considered a suitable measure to 
determine the degree of local inflammation in rarefacted tissue. It has been reported previously that 
the adenine-induced uremia model showed increased signs of inflammation, such as macrophage 
infiltration or fibrosis (Tamura et al., 2009). This may either reflect a direct effect of the adenine diet 
or may be a secondary effect of the much higher serum urea levels achieved by this method.  
It has been shown that endothelial cells which display an increased expression of ICAM-1 attract 
leukocytes by binding to leukocyte β2 integrin and thus contribute to a decelerated leukocyte rolling, 
increased diapedesis and the accumulation of pro-inflammatory cells in uremic tissue (Miyazaki et al., 
1997). These results are in contrast to some other authors, who observed diminished activation of β2 
integrin and increased leukocyte rolling velocity in mice with CKD ten days after subtotal nephrectomy 
(Rossaint et al. 2016).  
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In the present study, no correlation was identified between leukocyte rolling velocity and uremia 
(figure 5), rarefaction (figure 6), or IL-6 levels (figure 7). The significantly elevated IL-6 levels (figure 4), 
in particular, would have suggested an inflammatory response, measurable in a decreased leukocyte 
rolling velocity. It can be speculated that in small vessels, the influence of the already lower blood flow 
velocity and thus the already lower leukocyte rolling velocity, exceeds the effect of cytokine-mediated 
changes. The effects described by Rossaint et al. (2016) could also account for the leukocyte rolling 
velocity unaffected by inflammatory signals, as found in this study.  
Another effect in chronic inflammatory processes is fibrotic remodeling. Adenine-induced CKD leads 
to a significant increase in pro-inflammatory cytokines such as IL-1, IL-6 and TNF- (Santana et al., 
2013). A previous study revealed that the most dramatic decrease in VEGF expression in uremic 
animals could be shown in areas of the most pronounced macrophage infiltration (Kang et al., 2001). 
The authors showed that pro-inflammatory cytokines (IL-1, IL-6) reduced VEGF expression in their 
model. Since VEGF is not only a pro-angiogenic signaling molecule but also a factor determining 
endothelial cell survival (Gerber et al., 1998), an inflammation-induced drop in VEGF expression could 
explain the dramatic rarefaction in the microvasculature. The increase observed in IL-6 levels fits well 
with the concept that cytokines may hamper VEGF expression. While VEGF expression in the heart was 
not significantly influenced by uremia in this study (figure 20), a disruption of VEGF signaling due to an 
expression drop of VEGFR-2 (figure 23) could be shown.  
In addition, increased TGF- expression of inflammatory cells stimulates the production of ECM. 
Elevated TIMP1 levels inhibit MMPs and contribute to a further accumulation of ECM (Mutsaers et al., 
2015). 
 
4.7 Synopsis: A Hypothetical Model for Exacerbation of Endothelial 
Dysfunction in CKD 
In health, homeostasis of organ function and systemic conditions is usually maintained by a sensitive 
regulatory network. In recent years, there has been compelling evidence that CKD has a systemic 
impact on the microvasculature and organ function by interfering with this regulatory network.  
Kidney injury leads to the accumulation of detrimental compounds in the blood stream, including but 
not restricted to urea. The endothelial cell layer is at the forefront of this detrimental influence and it 
seems likely that endothelial cells and their sensitive signaling pathways to maintain vessel integrity, 
blood flow, and supply are battered by this condition. This gradual poisoning may lead to vascular 
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dysregulation and rarefaction, which has its beginning in the microvasculature well before any changes 
are detectable in larger vessels or end organs.  
As shown in this study, uremia leads to systemic microangiopathy which may be the starting point of 
a deteriorating disease process. Dysregulation and disruption of the terminal vessels may lead to 
persistent hypoxia which, in turn, may result in a prolonged inflammatory state, inhibiting an adequate 
response to insufficient oxygen supply on the expression level. This state could be considered a first 
step of decompensation: once an external confounding factor (as present in CKD, yet similar factors 
may exist in other conditions such as diabetes mellitus or hypertension) exceeds a certain threshold, 
this fine balance decompensates and complications of chronic illness may manifest with sudden onset.  
In a generic diagram (figure 45) deduced from the current state of understanding (Chade, 2011; Mayer, 
2011; Charytan et al., 2014; Korn & Augustin, 2015; Fu et al., 2016) and from results of this study, a 
number of vicious circles or feedback loops can be identified at first glance which may be established 
upon an initial endothelial damage. Some are described here in more detail. The rationales of these 
examples have already been described in the sections above. 
(1) Hypoxiamost simplymay lead to vascular rarefaction which in turn can aggravate hypoxia. 
(2) Reduced blood flow leads to hypoxia. Chronic hypoxia may lead to a prolonged inflammatory state 
which can trigger fibrosis. Increased extracellular matrix will hinder diffusion by increasing 
diffusion distances which in turn will increase hypoxia. 
(3) Fibrosis may lead to a reduced vessel compliance and thus, to an impairment of vascular tone 
regulation. Tone dysregulation may result in decreased blood flow and thus increase hypoxia.  
(4) Chronic hypoxia and prolonged inflammation may lead to a failure of HIF 1 transcription 
induction and thus, to dysregulated angiogenesis and to microvascular rarefaction. The 
abandoning of terminal vessels will then lead to functional shunting which will eventually further 
reduce blood flow in the microvasculature, thus increasing hypoxia.  
Upon closer analysis, even more complex loops can be identified which an organism—weakened by 
chronic illness—cannot counterbalance indefinitely. Therefore, once a system is destabilized and has 
entered into the vicious circles as shown in figure 45, disease condition can build up and progressively 
amplify: The condition is prone inevitably to worsen over time. Many of these failures may have a 
direct impact on the cardiovascular system and hence may trigger cardiac events without prior warning 
signs. These mechanisms may contribute to our understanding why in severe CKD clinically otherwise 
unobtrusive patients, such as children and adolescents, may suddenly decompensate, and ultimately, 




















Figure 45: A vicious circle of exacerbation in CKD. Hypothetical model of a dysregulated network in 
CKD following an initial endothelial damage (top, dashed arrow), e.g. from accumulating 
uremic toxins. Red arrows symbolize deleterious effects of network components on other 
elements of the system. The endothelium provides the basis for regulation of vascular tone 
and delivers essential factors for vessel integrity such as angiopoietins. Disturbance of 
endothelial function may lead to a reduced blood flow via multiple routes, and thus to 
tissue hypoxia. Chronic hypoxia triggers inflammatory processes and leads to dysregulated 
angiogenesis. These effects result in further damage to the endothelium and vessel 
integrity, respectively, further aggravating the disease process—the start of a vicious circle. 
Although it is evidently not possible to differentiate clearly between cause and effect in 
such a complex network, a deeper understanding of this regulatory circuit can provide 
valuable insight into possible counter-actions to stop or slow down the relentless 



















5 List of Abbreviations 
5/6 NX ............................................................ subtotal nephrectomy removing about 5/6 of renal tissue 
AGE ....................................................................................................... advanced glycation end products 
AKI ............................................................................................................................... acute kidney injury 
Ang ......................................................................................................................................... angiopoietin 
avΔO₂ ............................................................................. arterial-venous difference of oxygen saturation 
BALB/c ................................................................................................. Bagg albino inbred mouse strain c 
CAKUT .................................................................... congenital anomalies of the kidney and urinary tract  
cAMP ............................................................................................ 3',5'-cyclic adenosine monophosphate 
CCD ........................................................................................................................ charge coupled device 
CD ....................................................................................................................... cluster of differentiation 
cDNA ............................................................................................................... copy deoxyribonucleic acid 
CKD ........................................................................................................................ chronic kidney disease 
CVD ........................................................................................................................ cardiovascular disease 
CT ........................................................................................................................... computer tomography 
DNA......................................................................................................................... deoxyribonucleic acid 
ECM ............................................................................................................................ extracellular matrix 
EMA .............................................................................................................. European Medicines Agency 
eNOS ................................................................................................................endothelial NO synthetase 
ELISA .............................................................................................. enzyme-linked immunosorbent assay 
ESRD ..................................................................................................................... end stage renal disease 
FDA ............................................................................................................ Food and Drug Administration 
FGF ....................................................................................................................... fibroblast growth factor 
GFR .................................................................................................................... glomerular filtration rate 
HIF ....................................................................................................................... hypoxia-inducible factor 
ICAM ........................................................................................................ intercellular adhesion molecule 
ICD ............................... International Statistical Classification of Diseases and Related Health Problems 
IL ............................................................................................................................................... interleukin 
IMT........................................................................................................................ intima media thickness 
i.p. ....................................................................................................................... intraperitoneal injection 
KDIGO ................................................................................. Kidney Disease: Improving Global Outcomes 
MAP .............................................................................................................mean arterial blood pressure 
MMP .................................................................................................................... matrix metalloprotease 
MRI .............................................................................................................. magnetic resonance imaging 
mRNA .............................................................................................................. messenger ribonucleic acid 
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qPCR ........................................................................................... quantitative polymerase chain reaction 
RNA ................................................................................................................................... ribonucleic acid 
ROS ...................................................................................................................... reactive oxygen species 
RT-PCR .......................................................................... reverse transcription polymerase chain reaction 
SD ................................................................................................................................. standard deviation 
SEM ................................................................................................................ standard error of the mean 
TGF ................................................................................................................. transforming growth factor 
Tie ................................................. tunica interna endothelial cell kinase = TEK receptor tyrosine kinase 
TIMP ...................................................................................... tissue inhibitor of matrix metalloproteases 
TNF........................................................................................................................... tumor necrosis factor 
VEGF ................................................................................................... vascular endothelial growth factor 
VEGFR .................................................................................. vascular endothelial growth factor receptor 
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